



Brighter

Invitation to participate in a unit issue in Brighter AB (publ)

N.B. this is an unofficial translation of the EU growth prospectus which has been drawn up by the Company and approved by the Swedish financial supervisory authority on the 5th of February, 2021 (diary number 20-29924). In the event of any discrepancy between this English version of the EU growth prospectus, and the Swedish version thereof, the Swedish version shall prevail.

NOTE THAT THE UNIT RIGHTS ARE EXPECTED TO HAVE A FINANCIAL VALUE

So that the value of the unit rights is not lost, each holder must either:

- exercise the unit rights and subscribe for new units by February 23, 2021, or
- sell the unit rights that have not been exercised by February 19, 2021.

Important information

Certain definitions

Unless otherwise stated, the following definitions apply in this Prospectus.

“Brighter”, “the Company” or “the Group”, means Brighter AB (publ), with company number 556736-8591, and where applicable, the company group of which Brighter AB is the parent company. **“The Prospectus”** means this EU growth prospectus. **“The offer” or “the preferential rights issue”** means the offer to subscribe for units in Brighter in accordance with the terms in this Prospectus. **“Eminova”** means Eminova Fondkommission AB, with company number 556889-7887. **“Euroclear”** means Euroclear Sweden AB, with company number 556112-8074. **“First North”** means the Nasdaq First North Growth Market in Stockholm that is a so-called Multilateral Trading Facility (“MTF”), registered as a grown market for small and medium-sized enterprises, which does not have the same legal status as a regulated market.

General information

The Prospectus has been approved by the Swedish Financial Supervisory Authority, the qualified authority in accordance with Regulation (EU) 2017/1129 (“**the Prospectus Regulation**”). The Swedish Financial Supervisory Authority has approved this Prospectus only to the extent that it satisfies the requirements of completeness, comprehension and consistency as stated in the Prospectus Regulation. Approval of the Prospectus should not be considered as some form of support for the issuer as referenced in this Prospectus. Investors ought to make their own assessment of the suitability of investing in the securities referred to in the Prospectus. Disputes arising on account of the content of this Prospectus and related legal relationships must be settled exclusively by a Swedish court. Swedish material rights do not include application to this Prospectus, including documents belonging to the document. This Prospectus and the documents incorporated by reference will be available in electronic format on the Company’s website (www.brighter.se) throughout the validity period of the document.

Important information for investors

The offer to acquire shares in the Company in accordance with the terms and conditions in this Prospectus is not aimed at shareholders or other investors domiciled in the USA, Canada, Australia, New Zealand, Singapore, Hong Kong,

Japan or South Africa, or in any other country where participation in the rights issue would require additional offer documents or prospectuses, registration or measures other than those in accordance with Swedish Law, or that otherwise would contravene rules in such a country.

No subscription rights, purchased warrants, shares or other securities issued by Brighter have been registered or will be registered in accordance with the United States Securities Act 1933, or in accordance with securities legislation in any state of the USA or any provincial law in Canada. No subscription rights, purchased warrants, shares or other securities issued by Brighter may therefore be transferred or offered for sale in the USA or Canada other than in such exceptional cases where registration is not required. Notification of the acquisition of shares in contravention of the above can come to be deemed illegal and disregarded.

Market information and forward looking statements

The Prospectus contains certain forward looking statements and opinions. Forward looking statements are statements that are not related to historical facts and events and such statements and opinions that concern the future and that, for example, contain formulations such as “believe”, “estimate”, “envisage”, “expect”, “assume”, “forecast”, “intend”, “could”, “will”, “ought”, “should”, “according to estimates”, “have the intention”, “can”, “are planning”, “potential”, “predict”, “plan”, “as far as is known” or similar expressions, where the intention is to identify a statement as forward looking. This applies, above all, to statements and opinions in the Prospectus that address future financial returns, plans and expectations for the Company’s business and management, future growth and profitability and the general financial and legal environment and other issues that concern the Company.

Forward looking statements are based on estimates and assumptions that are made based on what the Company knows at the date of the Prospectus. Such forward looking statements are affected by risks, uncertainties and other factors that can lead to the actual financial performance, including the Company’s cash flow, financial position and operating profit/loss, differing, or not meeting expectations that were expressly or understood to

have been assumed or described in these statements, or prove to be less favorable than the financial performance that was expressly or understood to have been assumed or described in these statements. In a corresponding way, potential investors ought not put unreasonably high confidence in these forward looking statements and they are strongly advised to read the Prospectus in its entirety. The Company cannot provide guarantees of the future correctness of the opinions presented or whether the predicted developments are actually going to occur.

The forward looking statements published in this Prospectus are only valid at the time the Prospectus was made public and the Company offers no assurance of publishing updates or revisions of forward looking statements in the light of new information, future events or similar, other than that required by applicable laws and rules. The Prospectus contains information on the Company’s geographical markets, product markets, market size, market shares, market position and other market information related to Brighter’s business and market. The Company confirms that information from any third party has been reproduced correctly and that as far as the Company is aware and can determine from the information that has been published by a third party, no facts have been omitted that would render the information published incorrect or misleading.

Presentation of financial information

The figures reported in the Prospectus have been rounded in some cases, and therefore the tables in the Prospectus do not necessarily add up. All financial amounts are stated in Swedish (“**SEK**”) unless stated otherwise. “**KSEK**” refers to thousands of Swedish kronor, and “**MSEK**” refers to millions of Swedish kronor. Financial information in the Prospectus relating to the Company that is not included in the revised information or has been reviewed by the Company’s auditor in accordance with the stipulations herein originates from the Company’s internal audit and reporting system. Except where expressly stated, no information in the Prospectus has been reviewed or audited by the Company’s auditor.

Contents

Documents incorporated by reference	4
Summary	5
Responsible persons, information from a third party & approval of the relevant authority	11
Reasons for the offer	13
Strategy, results & enterprise climate	15
Statement on working capital	32
Risk factors	33
Information about the securities	36
The offer in more detail	39
Corporate governance	45
Financial information & key ratios	52
Legal issues, ownership and supplementary information	56
Available documents	61

Documents incorporated by reference

Investors should acquaint themselves with all the information incorporated in the Prospectus by reference, and the information to which reference is made must be read as part of the Prospectus. The information specified below as part of the following document must be considered to be incorporated in the Prospectus by reference. The elements of the documents that have not been incorporated by reference are either not relevant to investors or are reproduced elsewhere in the Prospectus. Other than the Brighter audited annual reports for financial years 2019 and 2018, no other information in the Prospectus has been inspected or audited by the Company's accountants.

Copies of the Prospectus and the documents that have been incorporated by reference may be obtained from Brighter electronically via the Company's website, www.brighter.se, or be obtained from the Company in hard copy format at the Company's head office at Borgarfjordsgatan 18, SE-164 40 Kista.

Note that the information on the Company's website, or other websites to which reference is made, is not included in the Prospectus unless this information is incorporated in the Prospectus by reference. The information on the Company's websites or websites to which reference is made in the Prospectus has not been reviewed or approved by the Swedish Financial Supervisory Authority.

The report for the period January 1–September 30, 2020

Consolidated income statement	Page 13
Condensed consolidated balance sheet	Page 14-15
Consolidated cash flow statement	Page 17
Notes	Page 21-26

The Interim Report is available at:

<https://mb.cision.com/Main/13292/3232961/1331822.pdf>

Audited annual report for the 2019 financial year

Consolidated income statement	Page 38
Condensed consolidated balance sheet	Page 39-40
Consolidated cash flow statement	Page 41
Notes	Page 46-76
Auditor's report	Page 78-79

The Annual Report is available at:

<https://brighter.se/download/1529/>

Audited annual report for the 2018 financial year

Consolidated income statement	Page 32
Condensed consolidated balance sheet	Page 33
Consolidated cash flow statement	Page 35
Notes	Page 40-67
Auditor's report	Page 69-71

The Annual Report is available at:

<https://brighter.se/wp-content/uploads/2020/01/Brighter-arsredovisning-2018-FINAL.pdf>

Summary

Section 1 - Introduction		
1.1	Name and ISIN of securities	The offer includes shares in Brighter AB (publ), ISIN code SE0004019545, and series TO6 subscription options, ISIN code: SE0015530910.
1.2	Name and contact details of issuer	The Company's business is (and trades as) Brighter AB (publ) co. no. 556736-8591. Head office and address: Borgarfjordsgatan 18, SE-164 40 Kista. Email: info@brighter.se Telephone number: +46 (0)8 550 088 20 Website: www.brighter.se LEI code: 5299001CH8K0RXYV047
1.3	Name and contact details of the supervisory authority that approved the Prospectus	The Prospectus has been inspected and approved by the Swedish Financial Supervisory Authority (Finansinspektionen), which can be contacted by phone +46 (0)8 408 980 00, and email, finansinspektionen@fi.se, postal address Box 7821, SE-103 97 Stockholm, and at their office at Brunnsgatan 3, SE-111 38 Stockholm.
1.4	Date of approval	The Prospectus was approved by the Swedish Financial Supervisory Authority on February 5, 2021.
1.5	Warning	This summary should be read as an introduction to the EU Growth Prospectus. All decisions on investing in securities should be based on the investor studying the whole prospectus. Investors can lose all or part of their capital. If a claim related to the information in an EU Growth Prospectus is made in a court of law, the investor that is the plaintiff according to national legislation in a member state can be obliged to pay the costs of translating the EU Growth Prospectus before legal proceedings are initiated. Civil law liability only covers those persons that have presented the summary, including translations of this, but only if the summary is misleading, incorrect or inconsistent compared to the other parts of the EU Growth Prospectus or if it, together with other parts of the EU Growth Prospectus, does not provide the key information that investors need when deciding whether or not to invest in the securities in question.

Section 2 Key information about the issuer		
2.1	Information about the issuer	<p>The Company's business is (and trades as) Brighter AB (publ) co. no. 556736-8591. The board has its registered address in the Municipality of Stockholm, where the Company's business is also managed. The Company was founded in Sweden on 5 July 2007 and registered with the Swedish Companies Registration Office (Bolagsverket) on 31 August 2007. The Company is a Swedish public limited company, that is regulated by the Swedish Companies Act (2005:551).</p> <p>Since 2007, Brighter has developed solutions for data driven and mobile healthcare. The aim is to enhance and make more efficient the information flow of valid health and treatment data between patient and care provider, and to optimize and improve the treatment and monitoring of patients with chronic conditions. Via simplified disease management and personal, data driven stimulus, the Company aims to help patients achieve greater compliance with their treatment, which can improve quality of life, reduce next of kin anxiety and free up care resources.</p> <p>Until the acquisitions of Camanio (2019) and Nectarine Health (2020), Brighter initially targeted diabetes care with the Company's Actiste® solution: the world's first support tool that combines all the functions required for the monitoring and treatment of insulin treated diabetes in one device.</p> <p>Besides the above, the Company has the Actiste Mini® unit, which is a smaller variant of the initial version where the insulin pen (injection functionality) has been replaced by a smaller tablet container and a storage container for consumables. The Company also owns Camanio AB, a company in the field of digital welfare technology that develops smart solutions for care in the home that focus on the individual; and Nectarine Health, which has developed an innovative holistic solution for the home comprising a discreet armband with sensors and nodes placed in power sockets in the home.</p> <p>Christer Trägårdh is the Company's acting CEO.</p>

		<p>The table below shows the Company's shareholders with at least 5% of shares or votes as at the date of approval of the Prospectus. The Company has no controlling shareholders. As far as the Board of Directors is aware, there are no shareholder agreements or other agreements between any of the Company's shareholders that aim to achieve joint influence over the Company or any other agreements that may lead to a change in control within the Company.</p> <table><tr><th>Name</th><th>Number of shares</th><th>Number of votes and capital</th></tr><tr><td>Avanza Pension</td><td>25,030,662</td><td>11.52%</td></tr><tr><td>Total above</td><td>25,030,662</td><td>11.52%</td></tr></table>	Name	Number of shares	Number of votes and capital	Avanza Pension	25,030,662	11.52%	Total above	25,030,662	11.52%																																																													
Name	Number of shares	Number of votes and capital																																																																						
Avanza Pension	25,030,662	11.52%																																																																						
Total above	25,030,662	11.52%																																																																						
2.2	Financial information on the issuer	<p>In the following section, selected financial information is presented in summary from Brighter's audited annual reports for 2019 and 2018 plus the Company's interim report for the period January 1–September 30, 2020, with comparative figures for the corresponding period in the previous year.</p> <p>Revenues and profitability</p> <table><tr><th>Amounts in KSEK</th><th>Jan-Dec 2019</th><th>Jan-Dec 2018</th><th>Jan-Sep 2020</th><th>Jan-Sept 2019</th></tr><tr><td></td><td>Audited</td><td>Audited</td><td>Not audited</td><td>Not audited</td></tr><tr><td>Revenues and profitability</td><td></td><td></td><td></td><td></td></tr><tr><td>Operating profit/loss</td><td>-79,810</td><td>-48,605</td><td>-125,386</td><td>-44,781</td></tr><tr><td>Profit/loss for the period</td><td>-89,685</td><td>-53,080</td><td>-127,970</td><td>-55,158</td></tr></table> <p>Assets and capital structure</p> <table><tr><th>Amounts in KSEK</th><th>Jan-Dec 2019</th><th>Jan-Dec 2018</th><th>Jan-Sep 2020</th><th>Jan-Sept 2019</th></tr><tr><td></td><td>Audited</td><td>Audited</td><td>Not audited</td><td>Not audited</td></tr><tr><td>Assets</td><td>255,664</td><td>170,616</td><td>384,047</td><td>218,184</td></tr><tr><td>Shareholders' equity</td><td>207,775</td><td>106,918</td><td>335,894</td><td>205,335</td></tr></table> <p>Cash flows</p> <table><tr><th>Amounts in KSEK</th><th>Jan-Dec 2019</th><th>Jan-Dec 2018</th><th>Jan-Sep 2020</th><th>Jan-Sept 2019</th></tr><tr><td></td><td>Audited</td><td>Audited</td><td>Not audited</td><td>Not audited</td></tr><tr><td>Cash flow from operating activities</td><td>-114,222</td><td>-68,249</td><td>-140,260</td><td>-53,815</td></tr><tr><td>Cash flow from investment activities</td><td>-38,492</td><td>-42,750</td><td>-88,729</td><td>-24,387</td></tr><tr><td>Cash flow from financing activities</td><td>153,023</td><td>110,013</td><td>234,049</td><td>101,683</td></tr></table> <p>Auditor's reports</p> <p>The auditor's report for financial year 2018 includes the following comments: Disclosure of particular importance Without prejudice to our statements above, we wish to draw attention to the management report, which states that the Company is in need of additional capital in order to finance both the Company's long-term and short-term liquidity needs. The Company's liquidity needs depend on how successful it will be in commercializing its Actiste product in combination with whether or not funding current operational activities can be done with external funds. In order to ensure financing of the company's business, it is of the utmost importance that the financing of such takes place according to the options that the Board of Directors and management deem plausible."</p> <p>Key ratios</p> <p>Brighter uses certain financial key ratios not calculated according to IFRS. The Company feels that these key ratios provide valuable information for investors as they enable an assessment of current trends in a better way in combination with other key ratios that are calculated in accordance with IFRS. As different companies do not always calculate these key ratios in the same way, it is not certain that the information below can be compared to key ratios with the same designations as those of other companies. The Company considers that these key ratios provide a better understanding of its financial development.</p>	Amounts in KSEK	Jan-Dec 2019	Jan-Dec 2018	Jan-Sep 2020	Jan-Sept 2019		Audited	Audited	Not audited	Not audited	Revenues and profitability					Operating profit/loss	-79,810	-48,605	-125,386	-44,781	Profit/loss for the period	-89,685	-53,080	-127,970	-55,158	Amounts in KSEK	Jan-Dec 2019	Jan-Dec 2018	Jan-Sep 2020	Jan-Sept 2019		Audited	Audited	Not audited	Not audited	Assets	255,664	170,616	384,047	218,184	Shareholders' equity	207,775	106,918	335,894	205,335	Amounts in KSEK	Jan-Dec 2019	Jan-Dec 2018	Jan-Sep 2020	Jan-Sept 2019		Audited	Audited	Not audited	Not audited	Cash flow from operating activities	-114,222	-68,249	-140,260	-53,815	Cash flow from investment activities	-38,492	-42,750	-88,729	-24,387	Cash flow from financing activities	153,023	110,013	234,049	101,683
Amounts in KSEK	Jan-Dec 2019	Jan-Dec 2018	Jan-Sep 2020	Jan-Sept 2019																																																																				
	Audited	Audited	Not audited	Not audited																																																																				
Revenues and profitability																																																																								
Operating profit/loss	-79,810	-48,605	-125,386	-44,781																																																																				
Profit/loss for the period	-89,685	-53,080	-127,970	-55,158																																																																				
Amounts in KSEK	Jan-Dec 2019	Jan-Dec 2018	Jan-Sep 2020	Jan-Sept 2019																																																																				
	Audited	Audited	Not audited	Not audited																																																																				
Assets	255,664	170,616	384,047	218,184																																																																				
Shareholders' equity	207,775	106,918	335,894	205,335																																																																				
Amounts in KSEK	Jan-Dec 2019	Jan-Dec 2018	Jan-Sep 2020	Jan-Sept 2019																																																																				
	Audited	Audited	Not audited	Not audited																																																																				
Cash flow from operating activities	-114,222	-68,249	-140,260	-53,815																																																																				
Cash flow from investment activities	-38,492	-42,750	-88,729	-24,387																																																																				
Cash flow from financing activities	153,023	110,013	234,049	101,683																																																																				

2.2	Cont. Financial information on the issuer	<table><tr><th>KSEK</th><th>Jan-Dec 2019</th><th>Jan-Dec 2018</th><th>Jan-Sept 2020</th><th>Jan-Sept 2019</th></tr><tr><td>Operating profit/loss</td><td>-79,810</td><td>-48,605</td><td>-125,386</td><td>-44,781</td></tr><tr><td>Net financial items</td><td>-9,875</td><td>-4,475</td><td>-2,584</td><td>-10,377</td></tr><tr><td>Profit/loss before tax</td><td>-89,685</td><td>-53,080</td><td>-127,970</td><td>-55,158</td></tr><tr><td>Balance sheet total</td><td>255,664</td><td>170,616</td><td>384,047</td><td>218,184</td></tr><tr><td>Equity/assets ratio %</td><td>81%</td><td>63%</td><td>87%</td><td>94%</td></tr></table>	KSEK	Jan-Dec 2019	Jan-Dec 2018	Jan-Sept 2020	Jan-Sept 2019	Operating profit/loss	-79,810	-48,605	-125,386	-44,781	Net financial items	-9,875	-4,475	-2,584	-10,377	Profit/loss before tax	-89,685	-53,080	-127,970	-55,158	Balance sheet total	255,664	170,616	384,047	218,184	Equity/assets ratio %	81%	63%	87%	94%
KSEK	Jan-Dec 2019	Jan-Dec 2018	Jan-Sept 2020	Jan-Sept 2019																												
Operating profit/loss	-79,810	-48,605	-125,386	-44,781																												
Net financial items	-9,875	-4,475	-2,584	-10,377																												
Profit/loss before tax	-89,685	-53,080	-127,970	-55,158																												
Balance sheet total	255,664	170,616	384,047	218,184																												
Equity/assets ratio %	81%	63%	87%	94%																												
2.3	Principal risks that are specific to the Company	<p>Dependency on key persons Brighter is highly dependent on a number of key people. Losing one or more of them could delay the Company's product development and the commercialization of its products or make this more expensive. The company's ability to retain qualified staff is important in order to maintain Brighter's level of expertise, and there is a risk that the Company will not be able to retain these key personnel. Key personnel, the loss of whom would have the greatest impact on the business, are found in upper level management, quality assurance and regulatory issues, as well as in development.</p> <p>Brighter considers the probability of this risk crystallizing as medium. The Company deems that the risk, should it crystallize, would have a medium impact on the Company's competitiveness and financial position.</p> <p>Product liability There is a risk that the Company may face product liability claims if a product causes injury or damage to a person or property. There is a risk that the Company's current or future insurance cover would not be adequate to cover possible claims that can be raised concerning product liability. Brighter's products are related to human health and are healthcare technology products, so product liability is greater than in other sectors. The Company assesses that the requirements on product liability are relatively similar in most countries, and that the level of damage claims awarded is comparable in the countries where the Company trades today.</p> <p>Brighter considers the probability of this risk being crystallized as medium. The Company deems that the risk, should it crystallize, would have a medium impact on the Company's competitiveness and financial position.</p> <p>Risk of legal sanctions against the Company's regular CEO As Henrik Norström, the Company's regular CEO, has taken time out from his job due to the fact that he has been notified by the Swedish Economic Crime Authority that he is under suspicion of abuse of the securities market, there is a risk of a criminal conviction having an impact on the Company, both financially and organizationally.</p> <p>Brighter considers the probability of this risk being crystallized as medium. The Company assesses that the risk, were it to crystallize, would have a high financial and organizational impact.</p> <p>Risk of the infringement of the Company's intellectual property rights Brighter is dependent on its ability to register and maintain patents, and to protect other intellectual property rights and specific knowledge. Our patent portfolio is concentrated in an extremely competitive field with potential for large international corporations, making the defense of the patent portfolio harder. Where it deems it important for the future development of the Company, Brighter applies for patents and trademark protection for the method and products developed by the Company on selected markets. There is a risk that current or future patent applications will not result in approved patents. The industry in which Brighter trades is also characterized by rapid technological development. This means that there is a risk that new technologies and products will be developed that bypass or supersede the Company's current and future patents or other intellectual property rights. There is a risk that Brighter's competitors may, intentionally or otherwise, infringe the Company's patents. If deemed necessary, the Company will protect its patents and other intellectual property rights through legal action. However, there is a risk that Brighter will not be able to fully enforce its rights in legal proceedings.</p> <p>Brighter considers the probability of this risk being crystallized as medium. The Company deems that the risk, should it crystallize, would have a low impact on the Company's financial position.</p> <p>Processing of personal data The Company's business involves the processing of consumers' personal data, namely special categories of personal data in the form of details related to health. According to data protection legislation, the processing of special categories of personal data is subject to more stringent requirements with regard, inter alia, to security. Despite the Company's measures to maintain the security and integrity of personal data, it is possible that the Company's security measures regarding systems and other security procedures will not prevent unauthorized access, the disclosure of personal data or that the processing of personal data can otherwise be seen to be inadequate. This could harm the Company's reputation and result in the Company being held liable for damages and for administrative sanction penalties pursuant to data protection legislation and, as a consequence, result in increased costs and/or loss of revenue. If any of these events were to materialize, this could have an adverse effect on the Company's business, financial position and earnings. The Company considers the probability of this risk being crystallized as low.</p> <p>The Company assesses that the risk, were it to crystallize, would have a medium impact on the Company's earnings.</p>																														

Section 3 Key information on the securities		
3.1	Information on the securities, rights associated with the securities and dividend policy	<p>The shares in Brighter have been issued in accordance with the Swedish Companies Act (2005:551). Each share carries equal rights to the Company's assets and earnings. The rights associated with shares issued by the Company, including those rights arising from the Company's Articles of Association, can only be changed in accordance with the procedures specified in the above legislation. The shares in the Company are denominated in Swedish kronor (SEK) and have one class. All shares issued are fully paid and freely transferable. The ISIN code for Brighter shares is SE0004019545. As at the date of the Prospectus, there are 229,005,540 shares outstanding in the Company. Each share has a quotient value of 0.05 SEK.</p> <p>Each share entitles the holder to one (1) vote at the general meeting. Every shareholder is entitled to vote for all shares which the shareholder has in the Company.</p> <p>If the Company issues new shares, warrants or convertible bonds in the event of a cash issue or offset issue, shareholders generally have preferential rights, in accordance with the Swedish Companies Act, to subscribe to such securities in relation to the number of shares that were held prior to the issue.</p> <p>The shares in Brighter are not subject to an offer made as a result of a mandatory bid, right of redemption or redemption obligation. Nor have any public takeover offers been made with regard to the shares during the current or previous financial year.</p> <p>Any dividend will be resolved by the shareholder's meeting following a proposal by the Board of Directors. Dividend rights accrue to shareholders who are registered in the shareholder register maintained by Euroclear on the record date resolved at the shareholder's meeting. All shares in the Company are entitled to a dividend. If a shareholder cannot be contacted through Euroclear the shareholder retains claim on the Company in respect of the amount of dividend, subject to a regulated limitation period. Upon expiry of the limitation period, the full dividend amount accrues to the Company. There are no specific rules, restrictions or procedures regarding dividends payable to shareholders domiciled outside Sweden.</p> <p>It is the policy of the Board of Directors to invest available funds in the business for as long as it is deemed more advantageous to shareholder value than paying a dividend. Therefore, the Board of Directors is currently intending to allow the Company to balance any profits in order to fund growth and the running of the enterprise and consequently does not predict payment of any cash dividends over the next few years. The opportunity for Brighter to pay dividends in the future is dependent on a number of factors, such as future earnings, financial position, cash flows, the need for working capital, costs for investments and other factors.</p>
3.2	Share trading	<p>Shares in the Company will be traded on the Nasdaq First North Growth Market. The share will be traded under the stock symbol "BRIG" and has the ISIN code SE0004019545. When the preferential issue has been registered at the Swedish Companies Registration Office, newly issued shares will also be admitted to trading.</p>
3.3	Guarantees that the securities are covered by	<p>The securities are not covered by any guarantees.</p>
3.4	Principal risks that are specific to the securities	<p>Growth and liquidity of the share price</p> <p>Investors should consider an investment in Brighter to be speculative. Whether the share price will enjoy positive growth cannot be predicted. This means that there is a risk that investors could lose all or part of their invested capital. Historically, Brighter shares has been volatile in price, and it may also continue to fluctuate in the future due to variations in the Company's earnings as contained in its quarterly reports, the general economic climate and changes in the level of stock market interest in the Company and its shares. In turn, limited liquidity in the share may amplify such fluctuations in the share price. Average daily trading in the Company's share over the period January 1–November 30, 2020 was SEK 4,333,338 per day. This means that the share price may be affected by factors wholly or partially outside the control of the Company. Therefore, before investing in shares, investors should first undertake a detailed analysis of the Company, its competitors and the market, and should also look at general information about the sector, the general economic climate and other relevant information. There is a risk that shares in Brighter cannot be sold at a price that is acceptable to the shareholder at that time.</p> <p>Brighter considers the probability of this risk being crystallized as medium. The Company deems that the risk, should it be crystallized, would have a medium impact on the shareholder.</p>

Section 4 – Key information about the offer of securities to the public		
4.1	Terms and conditions and timetable for investing in the security	<p>Preferential right to subscribe</p> <p>Parties registered as shareholders in the Company on the record date February 5, 2021 have preferential rights for three (3) unit rights for one (1) existing share.</p> <p>Volume</p> <p>The offer includes no more than 98,145,231 units. If the offer is fully subscribed, approx. SEK 117.8 million will be injected into the Company initially, and a further amount of up to SEK 65.4 million may be injected into the Company if the subscription options are exercised in full.</p> <p>Subscription price</p> <p>The price per unit has been set to SEK 1.20, which is equivalent to SEK 1.20 per share. No commission will be charged.</p>

4.1	Cont. Terms and conditions and timetable for investing in the security	<p>Record date The record date at Euroclear Sweden AB (“Euroclear”) for establishing who is to receive unit rights in the issue is February 5, 2021. The last day of trading in the Company’s shares, including the right to receive unit rights is February 3, 2021. The first day of trading in the Company’s shares, excluding the right to receive unit rights, is February 4, 2021.</p> <p>Subscription period The subscription for units is to take place from February 9, 2021 to February 23, 2021 inclusive. The Board of Directors of the Company has the right to extent the subscription period. The Board of Directors will not be entitled to cancel the issue after the subscription period has begun.</p> <p>Unit rights Shareholders in the Company will receive three (3) unit rights for one (1) share held. Seven (7) unit rights are required to subscribe for one (1) unit. Unit rights that have not been sold by February 19, 2021 or not exercised to subscribe for shares at the latest by February 23, 2021 will be withdrawn from all securities accounts without reimbursement. No specific notice will be given when withdrawing unit rights.</p> <p>Trading in unit rights Trading in unit rights will be done on First North from February 9, 2021 to February 19, 2021 inclusive. Unit rights that are acquired during the above trading period will give the same right to subscribe for new units during the subscription period as the unit rights obtained by shareholders on the basis of their holdings in the Company on the record date. Banks and securities institutions with the necessary licenses will be available to broker the purchase and sale of unit rights.</p> <p>Trading in paid subscribed units (PSU) and conversion into shares Trading in paid subscribed units (PSU) will take place on First North from and including February 9, 2021 until the issue has been registered with the Swedish Companies Registration Office and the conversion from paid subscribed units (PSU) to units has taken place. The last day of trading will be announced by a market notice. Euroclear will not make a specific notification in connection with the conversion.</p> <p>Conditions for subscription of shares via TO6 subscription options Three (3) TO6 subscription options are required in order to subscribe for one (1) new share at a subscription price corresponding to the volume weighted average price (VWAP), measured over the period of fifteen (15) trading days concluding two (2) banking days before the start of the subscription period for the subscription options, but no less than SEK 1.20 and no more than SEK 2.00. Subscription of shares pursuant to TO6 subscription options will take place between October 18 and November 1, 2021. The subscription options have ISIN code SE0015530910. The company will be working to ensure that the subscription options are admitted to trading during the term of the option.</p> <p>Dilution In the event of a fully subscribed issue the share capital will increase by SEK 4,907,261.55, from SEK 11,450,277 to SEK 16,357,539. The number of shares will then be increased initially by a maximum of 98,145,231, from 229,005,540 to 327,150,771 shares. The newly issued shares will then make up approx. 30.0% of all outstanding shares. In the event of a fully subscribed issue, existing shareholders who do not subscribe for the proportion to which they are entitled will see their ownership in the Company diluted to a corresponding degree.</p> <p>If the over-allocation issue is exercised in full, the share capital in the Company will increase by a further SEK 1,472,178.45 to SEK 17,829,717.45, and the number of shares will increase by 29,443,569 to a total of 356,594,340 shares. The dilution effect from the over-allocation issue alone will amount to approx. 8.3%. The dilution effect will amount initially to around 35.8% in the event of full subscription in the preferential rights issue and full exercising of the over-allocation issue.</p> <p>If all series TO6 subscription options from the preferential rights issue and the over-allocation issue are exercised in full, the share capital in the Company will increase by a further SEK 2,126,480.01 to SEK 19,956,197.46, and the number of shares will increase by 42,529,600 to a total of 399,123,940. The dilution effect will amount to a total of approx. 42.6% in the event of full subscription in the preferential rights issue and the over-allocation issue and full exercising of all appurtenant series TO6 subscription options.</p> <p>Issue costs The total issue costs are estimated to amount to approximately SEK 20 million, which thus means net liquidity of approximately SEK 97.8 million from the present new issue in the event of full subscription, and net liquidity of a total of approx. SEK 163.2 million in the event of full exercising of the subscription options. These costs relate to project management, utilization of internal resources, drafting documentation, administration of the issue, inspection fees levied by authorities and guarantee compensation.</p>
-----	---	---

4.2	Reasons for the Offering and use of issue liquidity	<p>Over the last year, Brighter has attained a number of important operational targets in a number of countries in order to establish the Company's solutions for efficient, data driven healthcare. CE-approved Actiste® for insulin treated diabetes has recently received market approval in Saudi Arabia and the United Arab Emirates. Actiste Mini®, which extends the market potential for all diabetics, received CE approval last summer and also received market approval in Saudi Arabia in December. In December, Brighter entered into two five-year distribution agreements with companies in Nigeria and Ghana concerning the Actiste® product portfolio, and on receipt of market approval the distributors will be ordering at least 3,000 (Nigeria) and 1,500 (Ghana) subscriptions with a total initial value of approx. EUR 3.5 million. Brighter's two subsidiaries Camanio and Nectarine Health have developed well during the year. Camanio was recently awarded a nationwide framework agreement with SALAR (the Swedish Association of Local Authorities and Regions) concerning stationary security alarms and mobile security alarms. During the year, Nectarine Health as prepared its market introduction for consumers in the US, and this is planned to take place in the first six months of 2021.</p> <p>The composition of the Brighter Board of Directors has undergone changes over the last year, and now represents an overall breadth of skills and stability that is very relevant and valuable ahead of the ongoing commercialization phase. Brighter's commercialization process is progressing well, given the challenges caused in the care industry in general due to the pandemic, and that continued investments in both market launches and development work should take place according to the previously defined strategy. A number of factors also indicate that this work should take place with increasing intensity; for example, the approvals in Saudi Arabia took place more quickly than was previously predicted by the Company. The more aggressive initiative now recommended by the Board of Directors is taking place with a view to achieving major market penetration more quickly, and therefore requires injection of expansion capital.</p> <p>Brighter is of the opinion that the existing working capital as at the Prospectus date does not meet the Company's need for working capital over the next twelve-month period, given the current business plan. The Board of Directors has decided to implement the offer in order to implement the Company's expansion plans that have been brought forward and ensure that there is sufficient working capital for the Company's continued activities.</p> <p>Liquidity from the preferential share issue, as well as liquidity from any over-allocation issue, must be distributed proportionally over the following ranked measures:</p> <ul style="list-style-type: none"> • Market investments - 50% • Research & Development - 15% • Production - 35% <p>Over-allocation issue</p> <p>In the case of oversubscription, the Board of Directors, in accordance with a mandate granted by the general meeting on June 15, 2020, may make a decision on a targeted new issue of shares not exceeding 29,443,596 units at the same price as in the preferential rights issue ("the over-allocation issue"). If the over-allocation issue is fully subscribed, a further approx. MSEK 35.3 will be injected into the Company. Full exercising of all appurtenant TO6 subscription options will inject a minimum of approx. SEK 11.8 million and a maximum of approx. SEK 19.6 million into the company. The aim of the over-allocation issue, in the first instance, is to make it possible for any professional and institutional investors to be established as major owners in the Company; in the second instance, to meet the wishes of individuals who have submitted subscription commitments before the start of the subscription period or who may submit subscription commitments without the support of unit rights; and, in the third instance, to exercise the option of injecting further working capital into the Company.</p> <p>Advisors, interests and conflicts of interest</p> <p>The financial institution in association with the rights issue is Eminova. Eminova is also the Company's Certified Adviser in connection with ongoing trade on First North. Eminova has provided, and can in future come to provide, various financial, investment, commercial and other services to the Company for which Eminova has received and can come to receive respectively, payment. Eminova does not hold any shares in the Company and will neither purchase nor broker sales of the Company's securities. Eminova has not been involved in the structuring of the present transaction. Eminova's involvement in this specific commission solely consists of administrative services. Eminova has assisted the Company in compiling this Prospectus. As all information in the Prospectus originates from the Company, Eminova accepts no liability whatsoever in relation to existing and future shareholders in the Company and in respect of other direct or indirect financial consequences as a result of decisions on investment or other decisions that are based entirely or in part on details in the Prospectus.</p> <p>There are no conflicts of interest or potential conflicts of interest between the obligations of members of the Board of Directors and senior executives in respect of the Company and their private interests and/or other obligations.</p> <p>Other than the interests of the above parties in the preferential rights issue being completed successfully, it is assessed that there are no financial or other interests or any conflicts of interest between the parties that, in accordance with the above, have financial or other interests in the offer.</p>
-----	---	--

Responsible persons, information from a third party & approval of the relevant authority

Responsible persons

The board of Brighter is responsible for the information in the Prospectus. To the best knowledge of the board, the information provided in the Prospectus is factually correct and no information that could probably affect such facts has been omitted. The composition of the current Brighter board of directors is presented below.

Name	Position
Emilie Erhardt Winiarski	Acting Chairman of the Board of Directors
Christer Trägårdh	Director and acting CEO
Åsa Sjöblom Nordgren	Director
Habib Al Assaad	Director

Drawing up and registration of the Prospectus

This Prospectus has been approved by the Swedish Financial Supervisory Authority, which is the qualified authority in accordance with Regulation (EU) 2017/1129. The Swedish Financial Supervisory Authority approves this Prospectus only to the extent that it satisfies the requirements of completeness, comprehension and consistency as stated in Regulation (EU) 2017/1129. This approval should not be considered to be some kind of support for the issuer or for the quality of the securities as set out in the Prospectus. Investors ought to make their own assessment of the suitability of investing in this security. The Prospectus has been drawn up as an EU Growth Prospectus in accordance with Article 15 in Regulation (EU) 2017/1129.

Information from a third party

The Prospectus contains information from a third party. The Board of Directors affirms that the information from references and source references in the Prospectus has been reproduced correctly and that – as far as the Board of Directors is aware and can determine from the information that has been published by a relevant party – no facts have been omitted that would render the information published incorrect or misleading. The statements in the Prospectus are based on the assessments of the Board of Directors and the management, unless other grounds are specified.

Source reference

- The World Population Prospects 2019: Highlights, United Nations Department of Economic and Social Affairs.
- OECD [2019], Health at a Glance 2019: OECD Indicators, OECD Publishing, Paris, <https://doi.org/10.1787/4dd50c09-en>.
- Aging Populations Will Challenge Healthcare Systems All Over The World. Forbes article, April 2018.
- Dieleman JL, Squires E, Bui AL, et al. Factors Associated With Increases in US Health Care Spending, 1996-2013. JAMA. 2017;318(17):1668-1678. doi:10.1001/jama.2017.15927
- Digital transformation Shaping the future of European healthcare, Deloitte Centre for Health Solutions. September 2020
- Building the healthcare system of the future. World Economic Forum article, December 2020 <http://reports.weforum.org/digital-transformation/building-the-healthcare-system-of-the-future/>
- European Commission EXPH (Expert Panel on effective ways of investing in Health), Assessing the impact of digital transformation of health services, 20 November 2018
- Care anywhere: Moving healthcare closer to home. World Economic Forum article, December 2020. <http://reports.weforum.org/digital-transformation/care-anywhere-moving-healthcare-closer-to-home/>
- Coronakrisen blottar brister i äldreomsorgen. May 2020. Article from Stockholm University.
- COVID-19 has pushed digital health forward, but challenges still persist. HealthcareITNews article, September 2020.
- Digital health technologies addressing the pandemic. European Commission 2020.
- Applications of digital technology in COVID-19 pandemic planning and response. Lancet Digital Health 2020; 2: e435-40 Published Online June 29, 2020 [https://doi.org/10.1016/S2589-7500\(20\)30142-4](https://doi.org/10.1016/S2589-7500(20)30142-4)
- Globala målen för hållbar utveckling i samhället. <https://www.globalamalen.se/om-globala-malen/mal-3-halsa-och-valbefinnande/>
- International Diabetes Federation, December 2020. <https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html>
- International Diabetes Federation, December 2020. <https://www.idf.org/aboutdiabetes/type-2-diabetes.html>
- Swedish Diabetes Association website, December 2020. <https://www.diabetes.se/diabetes/lar-om-diabetes/>
- Swedish Diabetes Association website, December 2020. <https://www.diabetes.se/diabetes/leva/behandling/egenvard/>
- Journal, Indian Academy of Clinical Medicine Vol. 15, No. 1. January-March, 2014
- Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299-1307. Published 2016 Jul 22. doi:10.2147/PPA.S106821
- Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: A systematic review. Diabet Med. 2014; 32: 725-37. doi:10.1111/dme.12651
- Egede LE, Gebregziabher M, Echols C, Lynch CP. Longitudinal effects of medication nonadherence on glycemic control. A. Pharmacother. 2014; 48: 562-70
- Swedish Diabetes Association website, December 2020. <https://www.diabetes.se/diabetes/leva/blodsockerkontroll/>
- International Diabetes Federation, December 2020. <https://www.idf.org/aboutdiabetes/complications.html>
- Press release dated February 20, 2017. <https://news.cision.com/se/brighter-ab--publ-r/brighter-sluter-avtal-med-sonat-for-global-logistiklosning-,c2192868>
- Press release dated December 13, 2017. <https://news.cision.com/se/brighter-ab--publ-r/arkessa-brighter-ericsson-och-gemalto-ingar-partnerskap-om-global-uppkoppling-for-diabeteslosning,c2412735>

Reasons for the offer

Over the last year, Brighter has attained a number of important operational targets in a number of countries in order to establish the Company's solutions for efficient, data driven healthcare. CE-approved Actiste® for insulin treated diabetes has recently received market approval in Saudi Arabia and the United Arab Emirates. Actiste Mini®, which extends the market potential for all diabetics, received CE approval last summer and also received market approval in Saudi Arabia in December. In December, Brighter entered into two five-year distribution agreements with companies in Nigeria and Ghana concerning the Actiste® product portfolio, and on receipt of market approval the distributors will be ordering at least 3,000 (Nigeria) and 1,500 (Ghana) subscriptions with a total initial value of approx. EUR 3.5 million. Brighter's two subsidiaries Camanio and Nectarine Health have developed well during the year. Camanio was recently awarded a nationwide framework agreement with SALAR (the Swedish Association of Local Authorities and Regions) concerning stationary security alarms and mobile security alarms. During the year, Nectarine Health has prepared its market introduction for consumers in the US, and this is planned to take place in the first six months of 2021.

The composition of the Brighter Board of Directors has undergone changes over the last year, and now represents an overall breadth of skills and stability that is very relevant and valuable ahead of the ongoing commercialization phase. Brighter's commercialization process is progressing well, given the challenges caused in the care industry in general due to the pandemic, and that continued investments in both market launches and development work should take place according to the

previously defined strategy. A number of factors also indicate that this work should take place with increasing intensity; for example, the approvals in Saudi Arabia took place more quickly than was previously predicted by the Company. The more aggressive initiative now recommended by the Board of Directors is taking place with a view to achieving major market penetration more quickly, and therefore requires injection of expansion capital for all parts of the business.

Brighter is of the opinion that the existing working capital as at the Prospectus date meets the Company's need for working capital over the next twelve-month period, given the current business plan. The Board of Directors has decided to implement the offer in order to implement the Company's expansion plans that have been brought forward and ensure that there is sufficient working capital for the Company's continued activities.

Liquidity from the preferential share issue, as well as liquidity from any over-allocation issue, must be distributed proportionally over the following ranked measures:

- Market investments - 50%
- Research & Development - 15%
- Production - 35%

Over-allocation issue

In the case of oversubscription, the Board of Directors, in accordance with a mandate granted by the general meeting on June 15, 2020, may make a decision on a targeted new issue of shares not exceeding 29,443,596 units at the same price as in the preferential rights issue (**"the over-allocation issue"**). If the

over-allocation issue is fully subscribed, a further approx. MSEK 35.3 will be injected into the Company. Full exercising of all appurtenant TO6 subscription options will inject a minimum of approx. SEK 11.8 million and a maximum of approx. SEK 19.6 million into the company. The aim of the over-allocation issue, in the first instance, is to make it possible for any professional and institutional investors to be established as major owners in the Company; in the second instance, to meet the wishes of individuals who have submitted subscription commitments before the start of the subscription period or who may submit subscription commitments without the support of unit rights; and, in the third instance, to exercise the option of injecting further working capital into the Company.

Advisors, interests and conflicts of interest

The financial institution in association with the offer is Eminova. Eminova is also the Company's Certified Adviser in connection with ongoing trade on First North. Eminova has provided, and can in future come to provide, various financial, investment, commercial and other services to the Company for which Eminova has received and can come to receive respectively, payment. Eminova does not hold any shares in the Company and will neither

purchase nor broker sales of the Company's securities. Eminova has not been involved in the structuring of the present transaction. Eminova's involvement in this specific commission solely consists of administrative services. Eminova has assisted the Company in compiling this Prospectus. As all information in the Prospectus originates from the Company, Eminova accepts no liability whatsoever in relation to existing and future shareholders in the Company and in respect of other direct or indirect financial consequences as a result of decisions on investment or other decisions that are based entirely or in part on details in the Prospectus.

There are no conflicts of interest or potential conflicts of interest between the obligations of members of the Board of Directors and senior executives in respect of the Company and their private interests and/or other obligations.

Other than the interests of the above parties in the preferential rights issue being completed successfully, it is assessed that there are no financial or other interests or any conflicts of interest between the parties that, in accordance with the above, have financial or other interests in the offer.

Strategy, results & enterprise climate

Market overview

Brighter is active in the health technology and welfare sector and focuses on a number of widespread challenges driven by global changes in society, as described below. These challenges are largely based on demographic and social shift in the population, in combination with limited resources in society and increasing care costs. This is giving rise to a major need for increased efficiency and innovative solutions that can remedy or rectify the situation in both the short and the long term. The Company is also purpose-driven and hence focuses directly on ensuring that all of the Company's solutions also help to enhance quality of life for end-users. Most of the business is currently focused on solutions for connected and data driven diabetes care, as well as digital care and support in the home. The Company is of the opinion that its solutions can create new opportunities and assets for a broad group of interested parties: patients and their relatives, care providers, authorities and governments, insurance companies and employers, the pharmaceuticals industry, clinical research organizations and academic bodies.

Driving forces and trends

The Company is well positioned for long-term growth and operates at the point of intersection for long-term global trends that drive a need for transformation in line with Brighter's business portfolio and IP strategy.

Aging population growing

The world's population is still growing, albeit at a slower rate than before. The UN estimates that the growth rate now stands at approximately 80 million people per year and that the world's population will increase by approximately 2 billion people over the next 30 years. At the same time, a rapid increase in the average lifespan is bringing about an extensive demographic shift, elderly people (people aged 65+) being the fastest growing age group. It is estimated that by 2050, one in six people in the world will be aged over 65 (16%), compared with one in 11 in 2019 (9%). Regions where the proportion of the population aged 65 or above is expected to double between 2019 and 2050 includes North Africa and West Asia, Central and South Asia, East and South-East Asia and Latin America and the Caribbean. The UN also estimates that one in four people living in Europe and North America will be aged 65 or over by 2050. The number of people aged 65 or above recently (in 2018) exceeded the global number of children under five years of age for the first time in history. The number of people aged 80 or over is expected to triple, from 143 million in 2019 to 426 million in 2050¹. This demographic shift means that a declining proportion of the population needs to support an increasing proportion of the population which generally has greater need for support and care.

¹ The World Population Prospects 2019: Highlights, United Nations Department of Economic and Social Affairs.

Increased pressure on care and social functions

Financial sustainability is becoming more and more of a concern as most countries are largely financed through public funds.

In the OECD countries, care costs have exceeded the economic growth for most of the last half-century, and these costs are expected to continue to exceed GDP growth over the next 15 years according to the OECD report entitled “Health at a glance 2019”². The trend involving the increasing cost of care is global and is due in part to the demographic shift, where an increasing proportion of the population is living longer and needing more care, but also on the fact that the extent of chronic diseases such as diabetes is increasing significantly in society^{3, 4}. These parameters increase both the economic and the operational burden on social functions relating to care and nursing. This development clarifies the potential impact of the aging population on the labor market and economic development, as well as the fiscal policy pressure that many countries will encounter over the next few decades when they attempt to build and maintain public systems for health and medical care, pensions and social protection.

Digitalization and data in care

Improving the quality and availability of care while controlling costs when the population is aging and growing, the expected lifespan is increasing and public expenditure on care is under pressure is one of the biggest challenges facing care

organizations and societies all over the world⁵. Modern technology and digital development will play a key role in coping with these challenges without compromising on quality. The Company is of the opinion that the situation has created a universal need for an extensive transformation in which digital services, new innovations and altered working methods may add new value and bring about streamlining. This value can be added on many fronts; by preventing illness, enhancing medical quality, increasing the availability of care and improving the work environment for care and nursing staff. Individuals may also be given new tools so that they can get involved in their health and look after it, which may result in enhanced quality of life and less burden on the system over time.

Systematic application of digital technology in care may allow more emphasis to be placed on preventive measures and allow more care to be given remotely, in the home. This may relieve the burden on hospitals and clinics; while at the same time new channels for contact with care via video or messages using connected instruments, for example, may result in an increase in overall accessibility. Improved access to relevant patient information and treatment data from different care providers will make it possible to streamline care processes and avoid incorrect treatments. Digital solutions may also create conditions for significant medical progress when using analysis tools and high quality data that can help care providers to make diagnoses and adapt

² OECD (2019), Health at a Glance 2019: OECD Indicators, OECD Publishing, Paris, <https://doi.org/10.1787/4dd50c09-en>.

³ Aging Populations Will Challenge Healthcare Systems All Over The World. Forbes article, April 2018.

⁴ Dieleman JL, Squires E, Bui AL, et al. Factors Associated With Increases in US Health Care Spending, 1996-2013. JAMA. 2017;318(17):1668–1678. doi:10.1001/jama.2017.15927

⁵ Digital transformation Shaping the future of European healthcare, Deloitte Centre for Health Solutions. September 2020

care programs to suit individuals. All in all, there is much to indicate that digital services and connected instruments can make it possible to achieve sustainable cost development while maintaining or improving the quality of care^{6, 7, 8}.

COVID-19: accelerated development

The pandemic that spread rapidly in 2020 increased the burden on health systems all over the world, taking them close to breaking point. But while the crisis revealed existing problems with shortages of resources and preparedness⁹, it has also accelerated digital transformation in the care and nursing sector, with a greater desire to innovate among decision-makers and increased emphasis on the value of digital and connected instruments, artificial intelligence and digital services as a direct response to the pandemic, but also in the long term. The use of digital and connected care has increased in connection with the pandemic^{10, 11, 12}, and the Company is of the opinion that this will continue in the aftermath.

Agenda 2030 – Global Goals

The Global Goals are the most ambitious agenda for sustainable development ever taken on by the countries of the world. This initiative, which is being run by the United Nations together with the countries of the world, includes a total of 17 ambitious and universal goals. Goal 3 involves ensuring healthy lives and promoting well-being

for all at all ages. Good health is a basic prerequisite for the human ability to achieve full potential and contribute to the development of society. Human health is influenced by economic, ecological and social factors, and Goal 3 includes all dimensions and people of all ages. Investments in health through preventive initiatives and modern and effective care for all benefit the development of society in general and pave the way for basic human rights to well-being¹³. Therefore, these goals are a strong driving force in how health and medical care develop at a global level going forward and provide a basis for a range of international initiatives all over the world. The Company is of the opinion that this may benefit stakeholders who help to ensure that the goals can be achieved.

Diabetes in the world

Diabetes is one of the company's primary and most important focus areas. This disease presents one of the fastest growing health challenges of the modern era, and the number of adults living with diabetes has more than tripled over the last 20 years. Diabetes is a chronic disease that leads to extensive costs for society – USD 760 billion in 2019 – and impairs quality of life for many people living with the disease. The International Diabetes Federation estimates that around 460 million people are living with diabetes at the moment and that this number will increase to around 700 million

⁶ Building the healthcare system of the future. World Economic Forum article, December 2020 <http://reports.weforum.org/digital-transformation/building-the-healthcare-system-of-the-future/>

⁷ European Commission EXPH (Expert Panel on effective ways of investing in Health), Assessing the impact of digital transformation of health services, 20 November 2018

⁸ Care anywhere: Moving healthcare closer to home. World Economic Forum article, December 2020. <http://reports.weforum.org/digital-transformation/care-anywhere-moving-healthcare-closer-to-home/>

⁹ Coronakrisen blottar brister i äldreomsorgen. May 2020. Article from Stockholm University.

¹⁰ COVID-19 has pushed digital health forward, but challenges still persist. HealthcareITNews article, September 2020.

¹¹ Digital health technologies addressing the pandemic. European Commission 2020.

¹² Applications of digital technology in COVID-19 pandemic planning and response. Lancet Digital Health 2020; 2: e435–40 Published Online June 29, 2020 [https://doi.org/10.1016/S2589-7500\(20\)30142-4](https://doi.org/10.1016/S2589-7500(20)30142-4)

¹³ Globala målen för hållbar utveckling i samhället. <https://www.globalamalen.se/om-globala-malen/mal-3-halsa-och-valbefinnande/>

over the next 25 years¹⁴. The disease is often divided into two types: type 1 and type 2 diabetes. Around 90 percent of all people with diabetes suffer from type 2¹⁵.

Type 2 diabetes is either due to the body not being able to produce enough insulin or that body cells are unable to respond to insulin as well as they should. There are a number of factors that come into play and genetic inheritance plays a big role in the risk of developing type 2 diabetes. Other factors that have an influence are being overweight, an inactive lifestyle, stress and also high age as the risk of developing type 2 diabetes increases with age¹⁶.

The challenge with diabetes

People living with diabetes must take a great deal of responsibility for their own care, although health and medical care services can help by providing the right technical “tools”. For self-care, people have to be able to measure their own blood glucose levels, interpret the results and take the correct action; injecting the right amount of insulin at the right time, for example. Having a knowledge of how diet and physical activity affect blood glucose levels is another important element¹⁷. This makes extremely stringent demands of patients on a day-to-day basis between physical visits to medical centers. At the same time, studies of the subject indicate that up to 85% of diabetics fail to treat themselves correctly^{18, 19}.

It is difficult to establish the precise number as different methods used to assess compliance lead to varying results, but it is

broadly agreed that a lack of compliance is common among patients with diabetes²⁰. It is also well known that low levels of compliance in treatment are associated with poor clinical outcomes, including higher medical care costs, more long-term health complications, more hospital stays and increased mortality²¹. Hence there is a major opportunity to both increase quality of life for diabetics and reduce the burden on care services and society by supporting patients more extensively in their day-to-day treatment, introducing innovative solutions that facilitate and encourage increased compliance and help care providers to remotely give their patients better, more personalized advice.

Complications due to inadequate diabetes treatment

People with diabetes are at increased risk of developing a number of serious health problems and should attempt to achieve the best possible control of their blood glucose levels, with as few insulin sensations (sensations of low blood glucose levels) as possible. Good control of blood glucose levels is the single most important factor in avoiding acute problems and chronic complications due to diabetes. However, achieving control of blood glucose levels comparable with levels in healthy individuals is impossible for most people with diabetes²². High blood glucose levels over time may lead to serious diseases affecting the heart and blood vessels, eyes, kidneys, nerves and teeth. Moreover, people with diabetes are at greater risk of developing infections. Diabetes is a leading cause of cardiovascular disease, blindness,

¹⁴ International Diabetes Federation, December 2020. <https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html>

¹⁵ International Diabetes Federation, December 2020. <https://www.idf.org/aboutdiabetes/type-2-diabetes.html>

¹⁶ Swedish Diabetes Association website, December 2020. <https://www.diabetes.se/diabetes/lar-om-diabetes/>

¹⁷ Swedish Diabetes Association website, December 2020. <https://www.diabetes.se/diabetes/leva/behandling/egenvard/>

¹⁸ Journal, Indian Academy of Clinical Medicine Vol. 15, No. 1. January-March, 2014

¹⁹ Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. *Patient Prefer Adherence*. 2016;10:1299-1307. Published 2016 Jul 22. doi:10.2147/PPA.S106821

²⁰ Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: A systematic review. *Diabet Med*. 2014; 32: 725–37. doi:10.1111/dme.12651

²¹ Egede LE, Gebregziabher M, Echols C, Lynch CP. Longitudinal effects of medication nonadherence on glycemic control. *A. Pharmacother*. 2014; 48: 562-70

²² Swedish Diabetes Association website, December 2020. <https://www.diabetes.se/diabetes/leva/blodsockerkontroll/>

kidney failure and amputation in almost all high-income countries. Maintaining blood glucose levels, blood pressure and cholesterol at or near to normal levels can help to delay or prevent diabetes complications. This is why people with diabetes need regular checks and instruments so they can treat themselves correctly²³.

The Company's positioning

The aim of Brighter (also known as the “Brighter Innovation Group”) is to drive development towards a more efficient and sustainable health and welfare system by addressing some of the greatest challenges facing health and medical care: inefficiency, increasing costs and limited resources. Using innovation and technology as a basis, the Company is focusing on enhancing quality of life for people and optimizing the use of society's resources. The Group's solutions are facilitating a wide range of new options for a number of interested parties and challenging traditional approaches and boundaries in order to create change. By introducing new methods, services and products that add new value, Brighter is striving to become a leading company at the cutting edge of digital, data driven and connected care and nursing.

Customer groups and ecosystems

The Company addresses a number of interested parties and is mainly focusing on the following groups both now and in the immediate future.

Users and relatives

Improved support on a day-to-day basis and enhance quality of life The Company's combination of products and services, as well as various addressed business

areas facilitates digi-physical support for treatments, increased availability of care in nursing services and modern nursing and support in the home by means of robotics, digital services, sensors and artificial intelligence. Increased insights may also give relatives peace of mind and give users a greater sense of security.

Care providers and personnel

Greater accessibility, reduced administration, better decision data and more efficient working methods. Connected medical products, sensors and products in the home, as well as digital services, provide care providers with greater remote access to patients and give them more of an insight into users' day-to-day lives so that they can make decisions, work proactively and efficiently supply high-quality care and nursing.

Nations and governments

Improved public health, optimize use of social resources and data for long-term initiatives. Besides the direct effects of a healthier population and reduced pressure on important social functions, greater access to high-quality data generated by means of Brighter's platforms can form a basis for long-term initiatives, decisions and planning at society level.

The pharmaceuticals industry

Access to high-quality real world evidence data for development of medications. The growing biosimilar industry, a multibillion dollar market that is addressing the global need for more cost effective medications, is creating opportunities for Brighter to support pharmaceutical companies in their development of medications by providing valuable information related to the efficacy of medications, for example.

²³ International Diabetes Federation, December 2020. <https://www.idf.org/aboutdiabetes/complications.html>

Insurance companies and employers

Cost savings and increased efficiency. In medical care systems based on private insurance policies where employers are payers, solutions that improve treatment outcomes may lead to fewer days off sick and fewer subsequent complications, for example, thereby reducing the total need for care over time. Personal treatment data may also be used as a basis for decisions in insurance cases.

Research and academia

Data and insights can create better conditions for research and studies in the field

of public health, needs in care and nursing and needs in respect of specific diseases.

Competitive situation

Brighter has a broad business spanning a number of sectors, product families and geographical areas. The business competes with high innovative power, entrepreneurial corporate culture and groundbreaking solutions, and its ambition is to offer solutions that enhance and create new opportunities and fill a gap in the market.

Description of the business


The Company's business is (and trades as) Brighter AB (publ) co. no. 556736-8591. The company was founded in Sweden on July 5, 2007 and registered with the Swedish Companies Registration Office (Bolagsverket) on August 31, 2007. The company's business is regulated by and its shares have been issued in accordance with the Swedish Companies Act (2005:551). The provisions in the Articles of Association are no more far-reaching than stated in the Swedish Companies Act as regards amendment to the rights of shareholders. The Company's identification code for legal entities (LEI) is 5299001CH8KORXSYV047.

Brighter is a purpose-driven Group comprising a number of companies and brands in the health technology sector. By introducing groundbreaking technology and new

innovative services, the objective of the Group at a global level is to help improve people's health and lives as well as paving the way for more efficient and sustainable use of society's resources. Besides the wholly owned and controlled subsidiaries, Brighter has made a strategic investment in digital care provider Accumbo. The company is not dependent on other companies within the Group.

The registered office of the Board of Directors is in the municipality of Stockholm, at Borgarfjordsgatan 18, SE-164 40 Kista. The Company can be contacted on its website (www.brighter.se) or by email (info@brighter.se). Note that the information on the Company's website is not included in the Prospectus unless this information is incorporated in the Prospectus by reference (see the section entitled "Documents incorporated by reference").

Group structure



Business areas addressed

Proactive and data driven medical care

Brighter has developed unique solutions and services based on patented technology that aim to facilitate more proactive, efficient and data driven medical care, primarily with regard to diabetes. These are propriety solutions under the “Actiste” brand family. The solutions are based on a concept that Brighter refers to as “The Benefit Loop” – a personal, holistic and data centered approach to medical care. The Company has also made a strategic investment in Swedish digital care provider Accumbo, which focuses on hypertension (high blood pressure). Accumbo has successfully launched the Blodtrycksdoktor [Blood Pressure Doctor] service in Sweden and is now working in parallel on development of a similar service for diabetes [“Diabetesdoktor” [Diabetes Doctor]], which is based on Brighter’s technology.

Digital care and support in the home

Brighter has used acquisitions in 2019 and 2020 to expand into the “age-tech” and care sector, focusing on innovative technology and services for care and support in the home. Subsidiary Camanio has a broad product portfolio comprising both digital services and physical instruments.

Camanio has extended its portfolio in 2020 to include a number of services designed to facilitate the transition to more digital care.

Brighter’s other subsidiary, Nectarine Health, has developed an advanced AI platform with the aim of making it possible for people to live in their own homes for longer. The original product, which is used by hundreds of people at care homes for the elderly all over Sweden, was developed for professional use and aims to detect falls and alert care providers at care homes

for the elderly so as to improve response times and enhance the quality of care. The second generation of this solution has been devised in 2020 and focuses primarily on the consumer market.

IP and licensing

Since being founded, Brighter has focused significantly on building up a strong IP portfolio in the field of digital and connected care. The Company currently has around 70 approved patents globally and around 45 pending patent applications. Its patents constitute a number of patent families linked to 1) Combination of functions (measurement and injection) in a single device, 2) Actual dose of medication injected into the body, 3) Mobile checking of connected medical instruments, 4) AI driven checking of connected medical instruments, and 5) Microneedle technology.

The Company regards its IP portfolio, and the commercial licensing opportunities it creates, as a separate active business area with significant potential.

Products and services

Brighter

Brighter has developed a unique product platform based on the concept known by the Company as “The Benefit Loop” – a personal, holistic and data centered approach to medical care. This platform is based on patented technology for collection of data on specified biomarkers and injected volumes of medications with a view to paving the way for more efficient care and better treatment outcomes.



The Benefit Loop

The first application based on the platform is Actiste®, for treatment of insulin treated diabetes. Actiste® obtained EC certification (the CE mark) in September 2019. The Company has also developed a further application known as Actiste® Mini for treatment of non-insulin treated diabetes. Actiste® Many obtained EC certification (the CE mark) in July 2020. Actiste® and Actiste® Mini have since received market approval in the United Arab Emirates, and Actiste® has also been approved for the market in the United Arab Emirates. Both units are offered as part of a subscription service that, in addition to the device itself, includes digital support and overview by means of a mobile application, global “out-of-the-box” connection by means of state-of-the-art

eSIM technology and automatic refills of all necessary consumables (excl. insulin) directly to the home. The aim of this is to facilitate day-to-day treatment as much as possible for users with the aim of promoting increased compliance with the treatment. In combination with the option of sharing important treatment data with care providers, who are thus offered better insight and an opportunity to provide more individualized advice based on reality-based data, it is thought that the solution will be able to make a huge contribution to more efficient treatments and improved treatment outcomes for users over time.

The Actiste® device

Actiste is a combined product which has a blood sampling device, a blood glucose meter and an insulin pen in a single device. It is designed to make life easier for people with insulin treated diabetes and comes with its own built-in global “out-of-the-box” Internet connection by means of an eSIM, which means it is entirely independent of other devices. All data is saved automatically and synchronized thanks to the associated mobile application, no matter where the user is in the world. Actiste is easy to use and simple to carry and has smart storage for test strips, lancets and needles. The device is supplied as part of a subscription service, as described in the paragraph above.

The Actiste Mini® device

Actiste Mini is a smaller variant of the initial version, where the insulin pen (injection functionality) has been replaced with a smaller tablet container and a storage container for consumables. This solution can be used to take blood samples, measure blood glucose and check values over time, and is aimed primarily at people

who have non-insulin-dependent diabetes. Actiste Many is easy to use and simple to carry and has smart storage for test strips and lancets. Like Actiste, it has its own built-in “out-of-the-box” Internet connection and all data is saved automatically and synchronized thanks to the associated mobile application, no matter where the user is in the world. The device is supplied as part of a subscription service, as described in the paragraph above.



Camanio

Camanio is a digital welfare technology company that develops smart solutions for care in the home that focus on the individual. The Company's platform and digital care services easily and securely link elderly people, relatives and care providers. This allows both digital and physical care to be offered according to needs.

Camanio aims to enhance both quality of care and quality of life and make care more accessible to people who need it. Offering dignity to individuals and efficiency to the care organization are Camanio's guiding lights. The care nursing sector is facing extensive challenges, with major demographic changes and reduced access to personnel. The Company is absolutely certain that more and more care in nursing will take place in the home. That is why smart, new, dignified technology is an important piece of the puzzle in order to cope with the challenges of the future.

Camanio SmartCare is a cloud-based service platform that collates all welfare

technology in a single portal. This platform manages alerts, checks and administration in a cohesive interface that allows the care provider to customize the digital ecosystem in the home, with welfare technology, security alarms and sensors.

The platform offers a reliable, scalable infrastructure and also provides decision support, as well as providing a good overview of services used for care. It is easy to integrate new innovations by means of an open API, where necessary. The platform is modular, and the cost is based on the services that are actually used. There are products and services here that are directly developed by Camanio, but a wide selection of products from other manufacturers and partners is also available.

This means that the platform can be adapted to meet the unique needs and criteria of care activities.

”

This is precisely what we are looking for. A service platform that can link together the jumble of sensors while also providing an overview of alarms.

Company manager



As things stand at present, Camanio offers three service packages:

1. Camanio Trygg Hemma [Safe at Home], stationary security alarm
2. Camanio Trygg Ute [Safe Out], mobile security alarm
3. Camanio Trygga Möten [Safe Meetings], secure video meetings for care, checks and nursing meetings

These services include an option for custom rule definition and event-based alerts and notices. Camanio has also been awarded SALAR's framework agreement for mobile and stationary security alarms in 2020.

In connection with delivery, Camanio offers a SPOC service (coordinated project management) for implementation as agreed. The Company then follows up timeframes, budgets and quality. Camanio works with requirement specification, implementation, administration and support regardless of hardware and software, and establishes a sustainable cooperation model for

operational, tactical and also strategic planning together with the Company's customers. This allows Camanio to ensure customer satisfaction and a sustainable digitalization strategy for care activities.

Camanio believes in transparency and cooperation. No one party can handle the challenges facing care of the elderly, but we can make a great deal of progress by working together. Therefore, the Company's ambition is to work together with innovators and entrepreneurs, established companies and other industries in order to add value and create synergies. There are major opportunities to be taken and gains to be made by linking together different solutions for the sharing of infrastructure, underlying services, data and interfaces. It must be possible to realize these gains through cooperation in order to devise the best possible solution for the individual while also providing a good toolkit for safer care and nursing.

Nectarine Health

Being able to live independently while continuing to maintain well-being is something that many elderly people are aiming for. Nectarine Health uses innovative technology to help and inspire elderly people to live fuller, higher quality lives and reduce anxiety among relatives.

The need for our elderly people to be able to live in their own homes while maintaining their well-being and security has been absolutely crucial, not least in 2020. The social distancing required means that many people have been unable to visit their elderly relatives, and concern about their well-being has increased.

Nectarine Health has developed an innovative holistic solution for the home, comprising a discreet armband with sensors and nodes that are placed in power sockets in the home. This armband is designed to be discreet and comfortable and has a battery life of 9 months or more. The nodes are easy to install and send signals indicating movement in the home to a digital platform where data is converted into insights by means of AI-based algorithms.

This information is provided by a sensor in the armband that measures movement and acceleration. The technology analyses the individual user's common movement patterns, and on the basis of that establishes an insight into movement and acceleration as

part of the individual's day-to-day life. Sleep is an important indicator of well-being. Data indicating disruptions may indicate that sleep is being disturbed more than usual, or that the individual is moving less frequently than usual between rooms in the home. Using this data as the starting point, the technology detects any behavioral changes and can call attention to a change in general condition. If a person falls, the system can distinguish a clear pattern for this. The technology creates automatic real-time warnings in the event of such a strong deviation in movement and acceleration.

The AI-based algorithms means that the insights gradually become more precise as they get to know the user's behavioral patterns. These insights are based on data on triggering factors such as disruptions in activity levels in movements and sleep. In the event of disruptions, prohibitive data can offer more information such as the number of times the user wakes up in the night and the length of their periods of sleep, which can provide a more reliable basis for investigation than the subjective perception. This information may also facilitate matters if further investigation is needed. When action has been taken to promote health, data gathered can offer insights into whether the behavioral patterns have returned to normal – whether the individual is sleeping better, for example.

We know now that the general condition of elderly people often worsens after a fall, and we want to avoid this happening. As the Nectarine solution provides insights into the fact that the user is not sleeping as well or is unusually inactive, this may signal the fact that there is an increased risk of a fall or impaired health. When this signal is received, relatives can help the user to take proactive action and seek medical care

before too long, and before the risk has increased still further.

The user and the relative that the user chooses to invite views the information via an app which displays insights into changes and displays emergency situations such as falls as alerts. If the user falls but is able to get back up again, this insight can also provide the relative with peace of mind.

Besides the AI algorithms, this armband is distinguished by beautiful, stylish design, a battery life of around nine months and watertightness, which means that the user can wear the armband 24 hours a day. This in itself increases the amount of data available, which can then continuously improve the service and algorithms over time.

Nectarine Health is made up of a team of 40 people, 30 of whom are engineers who have developed the product's advanced hardware, software and artificial intelligence. The first generation of the technology is now being used in cooperation with Camanio in Sweden.

The second generation – a pure consumer version that underwent final development in 2020 – will be launched in the US in 2021. The commercialization team in the US will also be extended as a result of this. Broader global expansion is planned in the long term. Development of the product may facilitate matters for care stakeholders who focus on users in the home.



Geographical focus

Brighter has a global focus and is active in a number of parts of the world: Europe, South-East Asia, the Middle East and North America. Commercialization of the Nectarine service, the Actiste diabetes service, Camanio's solutions and Diabetesdoktorn in cooperation with associated company Accumbo are ongoing in Europe, primarily Sweden. In North America, the Company is focusing on welfare and care solutions via Camanio and Nectarine Health. The US is the primary market for the Nectarine company's newly developed consumer solution. In South-East Asia and the Middle East, Brighter is focusing entirely on commercialization of the Actiste diabetes service.





Business strategy and future prospects

The Company's strategy focuses on generating organic growth, and on driving synergies and increasing revenues throughout the entire Group by means of investments in existing activities and product platforms. The Group is diversified by geography, sector and service, which creates an opportunity to compensate for risks and challenges within an area with opportunities and growth somewhere else, where necessary.

Market introduction is achieved via local partnerships or own companies. In the United Arab Emirates, Brighter has established a subsidiary company together with a local partner, the AFAQ Group, ahead of commercialization of the Actiste service. Moreover, a regional branch has been set up in Jakarta, Indonesia, to provide a local presence and marketing effort in South-East Asia. Camanio's core business is in Sweden, but it also has a subsidiary in the US which works with the American market: this will also be an important element in Nectarine's US initiative. The Group works in partnership with leading organizations including Ericsson, Arkessa, Gemalto and Sonat in order to deliver the best results and experiences to customers and end-users.^{24,25}

Sales outlets and counterparties

Sales strategies and counterparties vary depending on geographical market and product, and are largely affected by the specific care in nursing system on the market. Thus public and private care stakeholders, authorities, insurance companies, distributors, larger employers and pharmaceutical companies are potential commercial counterparties. This also includes private individuals via direct sales.

Strategic objective

The Company is of the opinion that 2021 will involve a significant commercial shift for Brighter. Up to 2020, the primary emphasis has been on development, certifications, market approval processes and preparatory marketing initiatives. Brighter is now embarking upon 2021 with a clear objective and good conditions for generating revenues on a broad front with a number of revolutionary offerings, and on a number of markets.

²⁴ Press release dated February 20, 2017. <https://news.cision.com/se/brighter-ab--publ-/r/brighter-sluter-avtal-med-sonat-for-global-logistiklosning-.c2192868>

²⁵ Press release dated December 13, 2017. <https://news.cision.com/se/brighter-ab--publ-/r/arkessa--brighter--ericsson-och-gemalto-ingar-partnerskap-om-global-uppkoppling-for-diabeteslosninge,c2412735>

Revenue models

Sales of products and services

In the immediate future, most of the company's revenues are expected to be generated via sales of Group services and products. The Actiste diabetes service is sold as a subscription service where the pricing strategy is organic and is based on local willingness to pay. The aim of this type of pricing strategy is to maximize the number of users. The Company regards Actiste as a volume product where the value of the data that can be generated by many users has the potential to constitute a separate business area that can compensate for a lower price, which means that the service can be priced competitively on some markets with less of an ability to pay. The Nectarine service to be launched in the US in 2021 will also be sold as a subscription service.

Camanio offers both digital services and physical products, as well as both complete packages and customized holistic solutions. Camanio has undergone an extensive strategic shift in 2020, focusing more on its digital service offering.

Health and treatment data

In the long term, Brighter also intends to provide both the key to and the market platform for user-generated health data. The databases that, with user consent, are gradually generated in the Brighter platforms, can eventually be used in long-term social planning, national health initiatives, research projects, clinical studies and for the development of medical products. The aim is to offer social bodies and the pharmaceuticals industry access to the company's databases and insights for a fee so that users can receive payment for sharing their data.

Licensing of IP

Since 2007, the company has applied for and been granted a large number of

patents and registered designs in areas such as the integration of sample taking, measuring biomarkers and the injection of liquid medication in a single device and Artificial Intelligence supported monitoring functionality for medical equipment. An early focus on patents by Brighter's founders forms the basis of the Company's extensive patent portfolio. The Company has a number of patent portfolios and around 70 approved patents, as well as around 40 patent applications pending. The Company has approved patents all over the world; in Europe, the US, India, Indonesia, Brazil, Japan, South Korea, China and Mexico. The Company intends to license parts of its IP portfolio to external parties.

Current commercial position

Brighter has launched the Actiste diabetes service as a consumer offering in Sweden in 2020, as well as embarking upon a number of initiatives for gathering valuable data and user insights that can be used as a basis for further commercialization opportunities; by means of an ambassador program and partnerships with two medical centers, among other things. Moreover, the Company has established a partnership with the provincial government in West Java in Indonesia in respect of user tests with Actiste. Furthermore, the Company obtained market approvals for the Actiste service into of the company's primary markets – the United Arab Emirates and Saudi Arabia – in November 2020. This means that the Company can now proceed with executing its commercial activities in these countries. Further market approval processes are ongoing in Indonesia, Thailand, Singapore and Malaysia. The new product Actiste® Mini is also expected to be ready for market launch in 2021. The Company is contacted regularly by organizations wishing to examine the options for initiating commercial partnerships in respect of the Actiste family (both Actiste and Actiste

Mini), and the Company is in dialog with a number of parties in respect of sales opportunities and revenue-generating contracts. On December 30, 2020, the Company signed a total of two five-year distribution agreements, one in Nigeria and one in Ghana, with a potential total value of approx. EUR 182 million. The distribution agreement relating to Nigeria was signed with Wssonlines Nigeria Ltd, and the distribution agreement relating to Ghana was signed with Fretac Plus Ventures. The distribution agreement relates to the Company's diabetes product portfolio, Actiste® ("the Actiste service"). Both Actiste® and the newly developed Actiste® Mini are included in the agreement. When the market approvals are granted, each distributor will be ordering at least 3,000 subscriptions (Nigeria) equivalent to approx. EUR 2.3 million, and 1,500 subscriptions (Ghana) equivalent to approx. EUR 1.2 million.

The Company's diabetes solutions Actiste® and Actiste® Mini obtained market approval in Thailand on January 7, 2021.

Camanio is well established on the Swedish care market, and since the Company was founded Camanio has sold to more than 50% of municipalities in Sweden. Five new distributor contracts were signed in 2020. Moreover, Camanio has been awarded a national framework agreement with the Swedish Association of Local Authorities and Regions in respect of security alarms, and this will remain in force for 4 years. On a global level, Camanio works in partnership with over 22 universities and research organizations. The platform developed by Nectarine Health is now used by around a hundred people at care homes for the elderly all over Sweden. An advanced version of the technology which will be aimed at the consumer market has been completed in 2020 and will be launched

in the US in 2021. Nectarine will initially be launching the service via its own online store on the company's website before then developing a network of sales partners.

Nominations and certifications

Brighter is certified to ISO-13485 and has successfully CE-marked two solutions: Actiste® and Actiste® Mini. The Actiste device was presented with the prestigious Red Dot Award in 2018. The Company was also nominated as one of the most promising Nordic companies of the future in the 2018 Serendipity Challenge and won the Swecare Rising Star Award in 2019.

This year, the Actiste service was nominated by Fast Company as one of the best world-changing ideas, and the Company also won the Healthtech Unicorn Battle Europe as late as November 2020.

Camanio was named as one of the top 10 leading companies providing robotics solutions in 2018. The Company also won the Swecare Rising Star Award for 2018.

Nectarine Health won the "Public Award" in the 2020 Techarenan Challenge.

Loan and financing structure

There have been no material changes in loan and financing structuring since the end of September 30, 2020.

Financing

Historically, the Company has been financed through the new issue of shares. Brighter is in a phase of growth aiming at expansion over the next few years. Among other things, this means that no dividends are planned and that all cash flow, generated both internally and externally, will go on financing the Company's expansion.

Until the business generates a positive cash flow, operating expenses will be financed with equity in the form of new issues of shares such as this preferential share issue, convertible bonds or other venture capital. To finance further expansion, the Company may supplement its equity with traditional financing through loans. Future financing is expected to be done through the present preferential share issue and via sales revenues from Company business.

Investments

The Company has made no significant investments since the end of the last

reporting period until the date of the Prospectus. Nor does the Company have any ongoing significant investments, but it does invest regularly in product development.


Trends

Since the end of its last financial year, the Company has not noted any specific development trend when it comes to production, sales, inventory, costs and selling prices.

Proaktiv och datadriven sjukvård



Digital omsorg och stöd i hemmet



Statement on working capital

Brighter is of the opinion that the existing working capital as at the Prospectus date meets the Company's need for working capital over the next twelve-month period, given the current business plan. The Company estimates that there will be a shortage of working capital at some point towards the end of the first quarter of 2021 and that the deficit for the next twelve-month period will amount to approx. SEK 120 million.

The Board of Directors has decided to implement the offer in order to implement the Company's expansion plans that have been brought forward and ensure that there is sufficient working capital for the Company's continued activities.

In the event of full subscription of the offer,

initial net liquidity of approx. SEK 97.8 million will be injected into the Company, and a total net liquidity of approx. SEK 163.2 million in the event of full exercising of the subscription options. The Company has received subscription and guarantee commitments totalling approximately SEK 94.2 million, equivalent to approximately 80% of the offer. If anyone submitting subscription commitments fails to meet their obligations, and/or if the offer is not subscribed to an extent that would guarantee the Company's capital requirements for the above expansion plan, the Board of Directors intends to seek alternative external finance by means of a targeted new issue of shares, lending and/or other credit facilities, for example. If the Company does not have the opportunity to secure

sufficient external finance in order to cover the remaining shortfall in expansion capital, the Company may need to take action such as postponing capital-intensive investments. This could involve impaired liquidity, and the Company may be forced to stop the planned expansion or be forced to drive development of operations at a slower pace than desired. This in turn may lead to delayed or absent commercialization of the Company's products and services, and delayed or absent sales revenues.

Further capital acquisition may be implemented via the Board of Directors' mandate from the general meeting on June 15, 2020 to issue shares or other share-related securities after completion of the preferential rights issue.

Risk factors

The risks that are deemed to be significance to Brighter's operations, financial position and future development as at the date of this Prospectus are described below. In accordance with the Prospectus Regulation, the risk factors specified below are limited to such risks as are specific to the Company and/or the securities and significant for making a well-founded investment decision.

The risks are arranged into three main categories, and the risk factors that are deemed to be most relevant as at the date of the Prospectus are presented first in each category, while the risk factors are then presented in no particular order. If a risk factor can be assigned to more than one category, any such risk factor will be shown only once and in the most relevant category for such a risk factor. The assessment of respective risk is based on the likelihood of it occurring and the anticipated scope of the adverse effects of the risk, should it occur. Assessment is performed by means of a qualitative scale, with designations low, medium or high.

Operating risk

Dependency on key persons

Brighter is highly dependent on a number of key people. Losing one or more of them could delay the Company's product development and the commercialization of its products or make this more expensive. The company's ability to retain qualified staff is important in order to maintain Brighter's level of expertise, and there is a risk that the Company will not be able to retain these key personnel. Key personnel, the loss of whom would have the greatest impact on the business, are found in upper level management, quality assurance and regulatory issues, as well as in development.

Brighter considers the probability of this risk being crystallized as medium. The Company deems that the risk, should it crystallize, would have a medium impact on the Company's competitiveness and financial position.

Product liability

There is a risk that the Company may face product liability claims if a product causes injury or damage to a person or property. There is a risk that the Company's current or future insurance cover would not be adequate to cover possible claims that can be raised concerning product liability. Brighter's products are related to human health and are healthcare

technology products, so product liability is greater than in other sectors. The Company assesses that the requirements on product liability are relatively similar in most countries, and that the level of damage claims awarded is comparable in the countries where the Company trades today.

Brighter considers the probability of this risk being crystallized as medium. The Company deems that the risk, should it crystallize, would have a medium impact on the Company's competitiveness and financial position.

Legal risks

Risk of legal sanctions against the Company's regular CEO

As Henrik Norström, the Company's regular CEO, has taken time out from his job due to the fact that he has been notified by the Swedish Economic Crime Authority that he is under suspicion of abuse of the securities market, there is a risk of a criminal conviction having an impact on the Company, both financially and organizationally. Brighter considers the probability of this risk being crystallized as medium. The Company assesses that the risk, were it to crystallize, would have a high financial and organizational impact.

Risk of infringement of the Company's intellectual property rights

Brighter is dependent on its ability to register and maintain patents, and to protect other intellectual property rights and specific knowledge. Our patent portfolio is concentrated in a limited number of areas that are extremely competitive, with potential for large international corporations, making defense of the patent portfolio harder. Where it deems it important for the future development of the Company, Brighter applies for patents and trademark protection for the method and products developed by the Company on selected markets. There is a risk that current or future patent applications will not result in approved patents. The industry in which Brighter trades is also characterized by rapid technological development. This means that there is a risk that new technologies and products will be developed that bypass or supersede the Company's current and future patents or other intellectual property rights. There is a risk that Brighter's competitors may, intentionally or otherwise, infringe the Company's patents. If deemed necessary, the Company will protect its patents and other intellectual property rights through legal action. However, there is a risk that Brighter will not be able to fully enforce its rights in legal proceedings. Brighter

considers the probability of this risk being crystallized as medium.

The Company deems that the risk, should it crystallize, would have a low impact on the Company's financial position.

Personal data processing

The Company's business involves the processing of consumers' personal data, namely special categories of personal data in the form of details related to health. According to data protection legislation, the processing of special categories of personal data is subject to more stringent requirements with regard, inter alia, to security. Despite the Company's measures to maintain the security and integrity of personal data, it is possible that the Company's security measures regarding systems and other security procedures will not prevent unauthorized access, the disclosure of personal data or that the processing of personal data can otherwise be seen to be inadequate. This could harm the Company's reputation and result in the Company being held liable for damages and for administrative sanction penalties pursuant to data protection legislation and, as a consequence, result in increased costs and/or loss of revenue. If any of these events were to materialize, this could have an adverse effect on the Company's

business, financial position and earnings. The Company considers the probability of this risk being crystallized as low.

The Company assesses that the risk, were it to crystallize, would have a medium impact on the Company's earnings.

Risks relating to the share and the offer

Growth and liquidity of the share price

Investors should consider an investment in Brighter to be speculative. Whether the share price will enjoy positive growth cannot be predicted. This means that there is a risk that investors could lose all or part of their invested capital. Historically, Brighter shares has been volatile in price, and it may also continue to fluctuate in the future due to variations in the Company's earnings as contained in its quarterly reports, the general economic climate and changes in the level of stock market interest in the Company and its shares. In turn, limited liquidity in the share may amplify such fluctuations in the share price. Average daily trading in the Company's share over the period January 1–November 30, 2020 was SEK 4,333,338 per day. This means that the share price may be affected by factors wholly or partially outside the control of the Company. Therefore, before investing in shares, investors should

first undertake a detailed analysis of the Company, its competitors and the market, and should also look at general information about the sector, the general economic climate and other relevant information. There is a risk that shares in Brighter cannot be sold at a price that is acceptable to the shareholder at that time.

Brighter considers the probability of this risk being crystallized as medium. The Company deems that the risk, should it be crystallized, would have a medium impact on the shareholder.

Uncovered subscription and guarantee commitments

The Company has obtained subscription and guarantee commitments from existing and external investors worth approx. SEK 94.2 million, equivalent to approx. 80% of the preferential rights issue. These subscription and guarantee commitments are not covered by bank guarantees, blocked funds, pledging or similar arrangements. There is therefore a risk that parties that have entered into subscription or guarantee commitments will not be able to meet their obligations in respect of the Company.

The Company considers the probability of this risk crystallizing as low. The Company assesses that the risk, were it to crystallize, would have a high negative impact on the Company.

Information about the securities

General information

The shares in Brighter have been issued in accordance with the Swedish Companies Act (2005:551). Each share carries equal rights to the Company's assets and earnings. The rights associated with shares issued by the Company, including those rights arising from the Company's Articles of Association, can only be changed in accordance with the procedures specified in the above legislation. The shares in the Company are denominated in Swedish kronor (SEK) and have one class. All shares issued are fully paid and freely transferable. The ISIN code for Brighter shares is SE0004019545. As at the date of the Prospectus, there are 229,005,540 shares outstanding in the Company. Each share has a quotient value of 0.05 SEK.

Preferential share issue

On Friday, January 29, 2021, the Board of Directors resolved, on the basis of the mandate granted by the

annual general meeting of June 15, 2020, to undertake a new issue of shares with preferential rights for existing shareholders. The rights issue comprises a maximum of 98,145,231 units and may initially yield approx SEK 117.8 million for the Company on full subscription. A unit consists of one (1) share and one (1) free series TO6 subscription option, ISIN code SE0015530910. Any parties recorded as shareholders as at the record date will receive three (3) unit rights for every one (1) existing share. Seven (7) unit rights are required to subscribe for one (1) unit.

The offer is covered by subscription and guarantee commitments amounting to approx. SEK 94.2 million.

Voting rights at the general meeting

Each share entitles the holder to one (1) vote at the general meeting. Every shareholder is entitled to vote for all shares which the shareholder has in the Company.

Preferential rights in the case of new shares, etc.

If the Company issues new shares, warrants or convertible bonds in the event of a cash issue or offset issue, shareholders generally have preferential rights, in accordance with the Swedish Companies Act, to subscribe to such securities in relation to the number of shares that were held prior to the issue.

Entitlement to dividends, share of the Company's profit and proceeds in the event of liquidation

All shares in the Company carry equal rights to dividends and to the Company's assets and any surplus in the event of liquidation. Resolutions regarding dividends in a limited liability company are made by general shareholder meetings. Dividend rights accrue to shareholders that are registered in the shareholder register maintained by Euroclear on the record date determined at the shareholder's meeting.

Dividends are normally paid to shareholders as a cash amount per share through Euroclear, but payment can also be made in forms other than cash (dividend in kind). If shareholders cannot be contacted through Euroclear, the shareholder retains their claim on the Company in respect of the amount of dividend, subject to a limitation period of ten years. In the case of a limitation period, the dividend amount falls to the Company.

Central safekeeping of securities

Brighter is affiliated to the electronic securities system and is registered in a securities register pursuant to the Securities Depositories and Financial Instruments Accounts Act (1998:1497). This register is kept by Euroclear (Euroclear Sweden AB, Box 191, SE-101 23 Stockholm). No share certificates have been issued for the Company's shares as the account provision and registration of the shares is handled by Euroclear in the electronic record register. Shareholders who are entered in the shareholder register and noted in the record register are entitled to all share-related rights.

Authorization

At the general meeting held on June 15, 2020, the Board of Directors was authorized, on one or more occasions before the next general meeting, to make decisions on the new issue of shares, issue of warrants and/or issue of convertible bonds. Issues may take place with or without deviation from shareholders' preferential rights. The mandate involves a right to make decisions on issues with cash payment, payment via offset or payment with capital contributed in kind, and otherwise in conjunction with conditions referred to in Chapter 2, Art. 5, second paragraph 1–3 and 5 of the Swedish Companies Act.

The shares offered in the preferential rights issue will be issued pursuant to the mandate from the general meeting on June 15, 2020.

Registration of the offer at the Swedish Companies Registration Office

It is thought that the offer will be registered at the Swedish Companies Registration Office in around week 12, 2021. This time is preliminary and may be subject to change.

Taxation issues

Investors in this preferential share issue should be aware that the tax legislation in the investor's member state and the Company's country of registration can affect possible income from the securities. Investors are urged to consult independent advisors in respect of the tax consequences that may arise in connection with the offer.

Applicable rules in the case of takeover bids, etc.

The Swedish Takeover Act (2006:451) (LUA) contains fundamental provisions regarding public takeovers related to shares in companies the shares of which are traded on a regulated market in Sweden. The Act also contains provisions governing mandatory bids and defensive measures. Furthermore, pursuant to the Securities Markets Act (2007:528), a securities exchange has rules related to public takeover bids regarding shares traded on a regulated market that the securities exchange operates.

The Nasdaq Stockholm AB and Nordic Growth Market NGM AB securities exchanges have such rules

in place today. The Swedish Corporate Governance Board, the role of which is to promote good corporate governance and good practice on the Swedish stock market, recommends that, in all material respects, equivalent rules should be applied with regard to companies whose shares are traded on multilateral trading platforms such as the Nasdaq First North Growth Market. The applicable regulations for Brighter are the “Takeover rules for trading platforms” issued by the Swedish Corporate Governance Board on April 1, 2018. A takeover bid can apply to all or some of the shares, either in a voluntary manner

through a public takeover bid or through mandatory bidding, taking place when an individual shareholder, alone or together with related parties, holds at least 30 percent of the votes in a company. A public takeover bid can be as cash, through a share offer where new shares are offered in the purchasing company, or through a combination of the two. The offer may be conditional or unconditional. All shareholders may accept or reject the offer. If the bidder reaches 90% of the shares, they have the right to trigger compulsory redemption of such shares for which shareholders have previously rejected for the offer.

Compulsory redemption means that a majority owner holding 90% of shares in the company has a statutory right to redeem remaining shares that are not already held by the majority owner. Compulsory redemption can also be triggered for a minority owner when a shareholder has more than 90% of shares.

The shares in Brighter are not subject to an offer made as a result of a mandatory bid, right of redemption or redemption obligation. Nor have any public takeover offers been made with regard to the shares during the current or previous financial year.

The offer in more detail

Conditions and instructions

Record date

The record date at Euroclear Sweden AB (“Euroclear”) for establishing who is to receive unit rights in the issue is February 5, 2021. The last day of trading in the Company’s shares, including the right to receive unit rights is February 3, 2021. The first day of trading in the Company’s shares, excluding the right to receive unit rights, is February 4, 2021.

Subscription period

The subscription for units is to take place from February 9, 2021 to February 23, 2021 inclusive. The Board of Directors of the Company has the right to extend the subscription period. The Board of Directors will not be entitled to cancel the issue after the subscription period has begun.

Subscription price

The subscription price is SEK 1.20 per unit. A unit consists of one (1) share and

one (1) free series 6 (TO6) subscription option. No commission will be charged.

Unit rights

Shareholders in the Company will receive three (3) unit rights for one (1) share held. Seven (7) unit rights are required to subscribe for one (1) unit. A unit consists of one (1) share and one (1) TO6 subscription option. Unit rights that have not been sold by February 19, 2021 or not exercised to subscribe for units at the latest February 23, 2021, will be withdrawn from all securities accounts without reimbursement. No specific notice will be given when withdrawing unit rights.

Trading in unit rights

Trading in unit rights will be done on First North from February 9, 2021 to February 19, 2021 inclusive. Unit rights that are acquired during the above trading period will give the same right to subscribe for units during the subscription period as the unit rights obtained by shareholders on the basis

of their holdings in the Company on the record date. Banks and securities institutions with the necessary licenses will be available to broker the purchase and sale of unit rights.

Paid and subscribed units (“PSU”)

Subscription by payment will be registered at Euroclear as soon as possible, normally a few banking days following payment. After which, the subscriber will receive a securities notice confirming that the paid subscribed units (PSU) have been booked into the securities account. Subscribed units are designated paid subscribed units (PSU) until the rights issue has been registered with the Swedish Companies Registration Office.

Trading in paid subscribed units (PSU) and conversion into shares and subscription options

Trading in paid subscribed units (PSU) will take place on First North from and including February 9, 2021 until the issue has been

registered with the Swedish Companies Registration Office and the conversion from paid subscribed units (PSU) to shares and subscription options has taken place. The last day of trading will be announced by a market notice. Euroclear will not make a specific notification in connection with the conversion.

Over-allocation issue

In the event of oversubscription, the Board of Directors may decide to implement an over-allocation issue not exceeding 29,443,569 units at the same subscription price as in the preferential rights issue (“the over-allocation issue”). If the over-allocation issue is fully subscribed, a further approx. SEK 35,332,283.16 will be injected into the Company. Full exercising of all appurtenant TO6 subscription options will inject a minimum of SEK 11,777,428 and a maximum of SEK 19,629,046 into the company. The aim of the over-allocation issue, in the first instance, is to make it possible for any professional and institutional investors to be established as major owners in the Company; in the second instance, to meet the wishes of individuals who have submitted subscription commitments before the start of the subscription period or who may submit subscription

commitments without the support of unit rights; and, in the third instance, to exercise the option of injecting further working capital into the Company.

Conditions for subscription of shares via TO6 subscription options

Three (3) TO6 subscription options are required in order to subscribe for one (1) new share at a subscription price corresponding to the volume weighted average price (VWAP), measured over the period of fifteen (15) trading days concluding two (2) banking days before the start of the subscription period for the subscription options, but no less than SEK 1.20 and no more than SEK 2.00. Subscription of shares pursuant to TO6 subscription options will take place between October 18 and November 1, 2021. Subscription of shares via TO6 subscription options will involve an increase in share capital by a further SEK 1,635,753.85 in the event of full subscription. Full exercising will inject an additional minimum of SEK 39,258,092.40 and maximum of SEK 65,430,154.00 into Brighter before issue costs. The company will be working to ensure that the subscription options are admitted to trading during the term of the option.

Dilution

In the event of a fully subscribed issue the

share capital will increase by SEK 4,907,261.55, from SEK 11,450,277 to SEK 16,357,539. The number of shares will then be increased initially by a maximum of 98,145,231, from 229,005,540 to 327,150,771 shares. The newly issued shares will then make up approx. 30.0% of all outstanding shares. In the event of a fully subscribed issue, existing shareholders who do not subscribe for the proportion to which they are entitled will see their ownership in the Company diluted to a corresponding degree.

If the over-allocation issue is exercised in full, the share capital in the Company will increase by a further SEK 1,472,178.45 to SEK 17,829,717.45, and the number of shares will increase by 29,443,569 to a total of 356,594,340 shares. The dilution effect from the over-allocation issue alone will amount to approx. 8.3%. The dilution effect will amount initially to around 35.8% in the event of full subscription in the preferential rights issue and full exercising of the over-allocation issue. If all series TO6 subscription options from the preferential rights issue and the over-allocation issue are exercised in full, the share capital in the Company will increase by a further SEK 2,126,480.01 to SEK 14,197,326.00, and

the number of shares will increase by 42,529,600 to a total of 399,123,940. The dilution effect will amount to a total of approx. 42.6% in the event of full subscription in the preferential rights issue and the over-allocation issue and full exercising of all appurtenant series TO6 subscription options.

Trading in the shares

Shares in the Company will be traded on First North. The share will be traded under the stock symbol "BRIG" and has the ISIN code SE0004019545. When the rights issue has been registered at the Swedish Companies Registration Office, the newly issued shares and options will also be admitted to trading.

Preferential right to subscribe

Parties registered as shareholders in the Company on the record date February 5, 2021 have preferential rights for three (3) new units for seven (7) existing shares.

Directly registered shareholders, securities account holders

The shareholders or representatives of shareholders who are recorded in the share register by Euroclear on behalf of the Company as at the record date will receive a preprinted issue report with attached payment form,

a special application form and an application form for subscription without unit rights. A securities notice regarding the registration of unit rights on securities accounts will not be sent out.

Shareholders included in the list of pledge holders and trustees maintained in connection with the share register will not receive an issue statement but will be informed separately.

Nominee-registered shareholders, holdings in custody accounts

Shareholders whose holdings are nominee-registered at a bank or other nominee will not receive an issue statement. Subscription and payment will take place according to instructions from the nominee instead.

Subscription with unit rights, directly registered shareholders

Subscription takes place through payment to the specified bank account at the latest on Tuesday, February 23, 2021 in accordance with one of the following two options.

1) Pre-printed payment form, Issue statement
To be used if all unit rights are to be exercised. Subscription is by payment using the pre-printed payment form. Please note that no further action is

required for subscription and that subscription is binding.

2) Special application form
To be used if a different number of unit rights is to be exercised than what is stated in the preprinted issue statement, e.g. if unit rights have been bought or sold. Subscription is effected when both the specific application form and payment have been received by Eminova Fondkommission. The reference when making the payment is the number on the application form. Incomplete or incorrect subscription forms may be rejected. The application form can be sent by post (Not Special Delivery), email or fax. Please note that subscription is binding.

Dedicated application forms can be obtained from Eminova Fondkommission AB, tel. +46 (0)8 684 211 00, fax +46 (0)8 684 211 29, email info@eminova.se.

Shareholders domiciled outside Sweden

Directly registered shareholders with subscription rights, domiciled outside Sweden
Directly registered shareholders with subscription rights, not domiciled in Sweden and who cannot use the pre-printed payment form (issue statement) can pay in SEK through SWIFT as follows. Subscription is

effected when both the specific application form and payment have been received by Eminova Fondkommission.

Eminova Fondkommission AB
Biblioteksgatan 3, 3 tr
111 46 Stockholm, Sverige
BIC/SWIFT: NDEASESS
IBAN: SE2930000000032731
703059

Shareholders domiciled in certain other non-legitimate jurisdictions Shareholders domiciled in other countries where participation in the rights issue is wholly or partially the subject of legal restriction do not have the right to participate in the rights issue (for example Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, USA, Switzerland). These shareholders will not receive unit rights, issue statements or any other information about the rights issue. Eminova reserves the right to reject subscribers domiciled in countries where Eminova does not conduct business.

Subscription without the support of unit rights plus allocation

If not all units are subscribed pursuant to unit rights, the Board of Directors must make a decision on the allocation of remaining units on the basis of the framework for the highest amount for the issue. Applications to subscribe for units without the support

of unit rights must be made using the application form entitled "Subscription without unit rights", which is available to download from eminova.se. If more than one application form is submitted, only the first one received will be taken into account. No payment is to be made in connection with application! Please note that applications are binding. (Important information on investment savings account, individual pension savings accounts or endowment policies can be found under "Miscellaneous")

If an application relates to subscription in an amount of EUR 15,000 or more, a completed KYC and a certified copy of valid ID must be submitted with the application form. If the application relates to a legal entity, a valid registration certificate (no more than three months old) showing authorized company signatories must be submitted with the application form in addition to the KYC and ID.

Notification of allocation of units will be provided by submitting a transaction note. Payment must be made to bankgiro as instructed on the transaction note and is never deducted from a specified securities account or custody account. If payment is not made on time, the units may be transferred to someone else.

If the selling price in the event of such transfer will fall below the price as stated in the offer, the party which was originally allocated these shares may be liable to make all or parts of the difference. No message will be sent to the parties that did not receive the allocation.

Allocation must take place as follows:

In the first instance, shares must be allocated to the Company's previous shareholders who have stated their shareholding as at the record date, Friday, February 5, 2021, on the application form. In the event of oversubscription, allocation will take place pro rata in relation to the number of shares held as at the record date, and by means of the drawing of lots insofar as this cannot take place.

Secondly, allocation must take place to other individuals who have applied for subscription without the support of unit rights. In the event of oversubscription, allocation will take place pro rata in relation to the number of shares applied for, and by means of the drawing of lots insofar as this cannot take place.

Miscellaneous

The subscription for units with or without unit rights is irrevocable and the subscriber cannot withdraw their subscription.

Regarding subscription to an investment savings account, individual pension savings account or an endowment policy

Particular rules apply to the subscription of new shares where the custody account or securities account is linked to an endowment policy, individual pension savings account or investment savings account. The subscriber must contact their bank/nominee and follow their instructions regarding how to make the subscription/payment. Where subscription is not undertaken correctly delivery of the allocated units to these types of custody accounts will not be possible. Subscription is binding and submitted application forms cannot be recalled. It is the responsibility of the subscriber to ensure that subscription is carried out in such a way that delivery can be made to the specified custody account.

Regarding the delivery of subscribed securities

Inaccurate or incomplete details on the application form; registration with the Swedish Companies Registration Office; late payment from investors; the procedures of the administering bank or depository or other factors over which Eminova has no control; can delay the delivery of units to

the investor's securities account or custody account. Eminova cannot accept liability for losses or other consequences for an investor due to the timing of the delivery of units.

Announcement of the outcome of the share issue

The announcement of the outcome of the issue will be made in a press release from the Company as soon as possible following the end of the subscription period. It is thought that announcement of the outcome will take place on around Thursday, February 25, 2021.

Right to dividends

The new shares provide entitlement to dividends for the first time on the first record day for dividends after the new shares have been registered with the Swedish Companies Registration Office.

Share register

The Company share register containing the details of shareholders is administered by Euroclear Sweden AB, Box 191, 101 23 Stockholm, Sweden.

Subscription and guarantee commitments

The subscription commitments amount to approx. SEK 2.6 million, equivalent to approx. 2.2% of the offer. The Company has also received

guarantee commitments of up to SEK 91.6 million, equivalent to approx. 77.8% of the offer. The offer is this covered by subscription and guarantee commitments equivalent to up to approx. 80% of the offer, which have been provided by the parties referred to in the table on the next page. No remuneration will be paid for submitted subscription commitments. Remuneration for guarantee commitments submitted will be payable at ten (10)% of the guaranteed amount. The guarantee consortium has been coordinated by the Company and can be contacted at the Company's address. All subscription and guarantee commitments were entered into on January 29, 2021.

The subscription and guarantee commitments specified below are not covered. Subsequently, there is a risk that these commitments will not be fulfilled: see also the section entitled "Risk factors – Uncovered subscription and guarantee commitments" above.

Subscription and guarantee commitments

The table below summarizes the subscription and guarantee commitments entered into as at the date of submission of the prospectus.

Name	<u>Subscription commitments</u>		<u>Guarantee commitments</u>		<u>Total commitment</u>	
	Amounts in SEK	Percentage of offer	Amounts in SEK	Percentage of offer	Amounts in SEK	Percentage of offer
Christer Trägårdh	1,577,143	1.3%	0	0.0%	1,577,143	1.3%
Henrik Norström	1,013,049	0.9%	0	0.0%	1,013,049	0.9%
Formue Nord Markedsneutral A/S ¹	0	0.0%	33,800,000	28.7%	33,800,000	28.7%
Qualcon AB ²	0	0.0%	24,000,000	20.4%	24,000,000	20.4%
Modelio Equity AB (publ) ³	0	0.0%	21,800,000	18.5%	21,800,000	18.5%
Oliver Molse	0	0.0%	12,000,000	10.2%	12,000,000	10.2%
Total:	2,590,192	2.2%	91,600,000	77.8%	94,190,192	80.0%

¹ Østre Alle 102, DK-9000 Aalborg, Denmark.

² Eriksrogränd 8, SE-19478 Upplands Väsby, Sweden.

³ c/o INTERSOLIA, Riddargatan 35, SE-114 57 Stockholm, Sweden.

Corporate governance

Board of Directors

As of the date of this Prospectus, Brighter's Board of Directors consists of four members elected by the shareholders' meeting, including the Chair of the Board of Directors, all of whom are elected for the period to the next annual general meeting. According to the Company's articles of association, the Board of Directors shall consist of not less than three and no more than ten Members of the Board of Directors. The Members of the Board of Directors, their positions, dates of birth, the date they were first elected, whether they are considered independent of the Company and large shareholders and their shareholding in Brighter are described in the table below. The specified holdings of securities issued by the Company relate both to private holdings and holdings through companies where those officers exert a controlling influence.

Name	Position	Date of birth	Elected	Independent in relation to		Shareholding	Options
				The Company and corporate executive	The Company's major shareholders		
Emilie Erhardt Winiarski	Acting Chairman of the Board of Directors	1983	2020	Yes	Yes	0	0
Christer Trägårdh	Director and acting CEO	1963	2020	Yes	Yes	150,000	0
Åsa Sjöblom Nordgren	Director	1970	2020	Yes	Yes	0	0
Habib Al Assaad	Director	1980	2020	Yes	Yes	0	0



Emilie Erhardt Winiarski

Acting Chairman of the Board of Directors

Education/background: Emilie has more than a decade of experience from the Nordic and International health and medtech industry, specializing in commercialization and business development. In her last post, Emilie was the head of business development and commercialization at Ivbar, a leading supplier of advanced data analysis solutions for the care sector. Her previous experience includes the roles of Director of Healthcare Partnerships and Consulting at Getinge and Senior Consulting Manager at Philips Healthcare Transformation Services. Previously, Emilie has also worked on innovation and digitalization projects and advisory services, as well as in customer and partner development at BUPA London and Sirona Health Solutions.



Christer Trägårdh

Board of Directors and acting CEO

Education/background: Christer Trägårdh most recently worked as the head of Swedish Banking Operations at Swedbank and has extensive experience of board work. Christer Trägårdh has worked in the banking industry for a long time and has extensive experience of board work in various industries. Christer was a member of Swedbank's group executive between 2014 and 2019; initially as a regional manager, and from 2016 as the head of Swedish Banking Operations, the group's biggest business area. Prior to this, Christer was the CEO of Bergslagens Sparbank and has also worked in various executive positions at Handelsbanken for 20 years. Christer has also been a member of around 20 boards, including as Chair of Fastighetsbyrån, Vice Chair of Svensk Handel Försäkringar (now SH Pension) and as a director at UC.

Åsa Sjöblom Nordgren

Member of the Board of Directors

Training/background: Åsa is the CEO and founder of Trice Imaging Inc., a leading stakeholder in cloud-based medical imaging. The Trice solution is approved and available in 42 countries and can be found in leading machinery from companies such as GE Healthcare, Philips and Fujifilm. Trice has expanded its global distribution and online sales directly to medical care stakeholders. Åsa has extensive experience of innovation and digitalization work, and of altering consumer behavior in the field of medical care. Åsa has previously held senior executive positions at Metronome, Sverige Kommunikatörer, MobPal Mobile Relations and Tre.



Habib Al Assaad

Member of the Board of Directors

Education/background: Habib Al Assaad is an international senior executive who is currently trialling “post-COVID-19” strategies and as an advisor to selected members in the ruling families of Dubai and Abu Dhabi. His previous advisory services to various stakeholders extend over 66 countries and included the Managing Directorship at Harvard Square’s MIRAKI Innovation, whose heritage includes seed financing of what is historically the largest medical exit (Auris to J&J) – CO-Executive Director at AFA Q-gruppen for General Investments, acting COO at Revitalife Compounding Pharmacies and Clinics, one of the founders of the Impact Hub network and ORYXIS 1 Bank, and various roles at ORACLE, GM, Motorola and Andersen Consulting. He is a former member of the Hawkamah Institute for Corporate Governance and an original member of the INSEAD Social Entrepreneurship program.



Senior executives

Christer Trägårdh

Board of Directors and acting CEO

For more information, see the section entitled “Board of Directors”.



Ann Zetterberg

Head of Finance

Education/background: Zetterberg has over 20 years experience as a CFO, including roles in both the venture-capital and technology start-up sectors. She also spent a number of years as CFO of Svenska Jägareförbundet, a not for profit hunting association. She is experienced in due diligence, M&As and in company financing. She is also Chair of the Board of Directors of Copperstone Resources AB. She has a degree in Business Administration from Stockholm University.

Holdings in the Company: 73,380 shares and 909 options TO5.



Jonas Johansson

Head of Research and Development

Education/background: Jonas holds a master’s degree in data and systems science from Luleå University of Technology. He has more than 15 years of experience of various senior positions in the field of medtech and has previously worked with companies such as St. Jude Medical, Saab and Elekta. Jonas heads Brighter’s R&D team and makes sure that Brighter supplies high quality products while remaining at the cutting edge of development.

Holdings in the Company: none.



Nadezda Ershova

Head of QA/RA (interim)

Education/background: Nadezda is one of the very first people the Company took on. She started working at Brighter, doing work experience when studying entrepreneurship and innovation at the Royal Institute of Technology. She now heads the Company's important quality and regulation work, which ensures that the correct framework is maintained and that the Company achieves the highest standards. Nadezda has a master's degree in Biology from Russia's Novosibirsk State University.

Holdings in the Company: 21,518 shares and 576 options TO5.



Yulianto Blom

Head of Production

Training/background: Yulianto heads the Company's product manufacturing work. Yulianto has experience of business planning work, Lean Production and supply chain management and has more than 15 years of experience of teambuilding and establishing new production plants. Before he started working at Brighter, he managed the supply chain for a currency manufacturer. Yulianto is a European Logistics Association certified logistician and studied law at Södertörn University.

Holdings in the Company: 3,436 shares and no options.



Dragan Zdravkovic

Head of Medical Affairs

Education/background: Dragan holds a medical degree and a master's degree in endocrinology. He is very experienced in pharmaceuticals, with more than 17 years of experience in various roles relating to medical issues, clinical research and business development at state-of-the-art pharmaceutical companies. Dragan is passionate about grappling with challenges and unmet needs in the field of diabetes management and heads Medical Affairs at Brighter, providing scientific insight and a medical background in order to support Brighter and its objectives.

Holdings in the Company: 245,000 shares and no options.





Maja Roslund

Head of People and Culture

Education/background: Work experience specialist Maja's job is to make Brighter grow by picking out the best in every staff member and helping the Company to be an attractive employer. Maja has studied leadership, education and organizational development, specializing in organization management. She has worked on a number of HR, management and corporate culture change assignments, including as acting CEO for an HR consultancy, and established a subsidiary in Sweden and China for the Unilever brand Blueair.

Holdings in the Company: 15,000 shares and no options.

Remuneration of the Board of Directors and senior executives

Fees to directors elected by the general meeting are decided upon by the annual general meeting. At an extraordinary general meeting held on July 31, 2020, a decision was made to pay fees to the Board of Directors for the coming mandate period, amounting to SEK 300,000 to the Chair of the Board of Directors and SEK 150,000 each to other members appointed by the general meeting. The decision was also made to pay a further SEK 20,000 to members of the remuneration committee and the audit committee. At an extraordinary general meeting held on November 20, 2020, a decision was made

to pay a fee to newly elected director and Chair Christer Trägårdh from January 1, 2021 until the end of the forthcoming general meeting, and for this fee to be paid according to the decision made by the extraordinary general meeting on July 31, 2020. The table below shows remuneration and other benefits to Brighter's Board of Directors and senior executives for the 2020 financial year. Total amounts in SEK.

The Company has no provisions or accrued expenses for pensions, benefits or similar when directors or management team members relinquish their appointments.

Position and name	Basic salary, board fees	Invoiced fees	Pension contributions	Total
Chairman, Erhardt Emilie	108,065	0	0	108,065
Director, Al-Assaad Habib	62,500	0	0	62,500
Director, Andersson Tove	53,492	171,645	0	225,137
Director, Flening Lars	41,665	0	0	41,665
Director, Ihre Catarina	41,667	0	0	41,667
Director, Lipsschutz Emanuel	53,492	44,100	0	97,592
Director/Chairman, Sjöstedt Truls	116,662	0	237,545	354,207
Director, Stålemark Jan	53,492	1,081,650	0	1,135,142
Director, Sjöblom Nordgren Åsa	0	0	0	0
CEO Henrik Norström	1,846,884	0	344,287	2,191,171
Other senior executives	3,739,639	6,000,429	1,262,490	11,002,558
TOTAL	6,117,559	7,297,824	1,844,322	15,259,705

Other information about the board of directors and senior executives

On June 24, 2020, the Company was notified that its former Chair, Truls Sjöstedt, had been taken in for questioning by the Swedish Economic Crime Authority. Later the same day, Jonas Myrdal, responsible prosecutor at the Swedish Economic Crime Authority, confirm that the individual in question was being detained and that a preliminary investigation had begun. Truls Sjöstedt was set free on June 26, 2020 and rejected all accusations, and intends to cooperate fully with the investigation. The preliminary investigation was not complete as at the date of approval for the Prospectus.

On December 23, 2020 the Company was notified by its regular CEO, Henrik Norström, that the Swedish Economic Crime Authority had notified him that he was under suspicion of abuse of the securities market for events linked to the information flow in the targeted issue that was announced in autumn 2019. Henrik Norström denies any wrongdoing and was not detained. Due to the investigation being carried out by the Swedish Economic Crime Authority, Henrik Norström chose to voluntarily take time

out from his position as CEO. This decision was made in discussion and consensus with the Company's Board of Directors. Christer Trägårdh is the acting CEO as of January 1, 2021, while also joining the Board of Directors. None of the Members of the Board of Directors or members of the management has family ties to other Members of the Board of Directors or members of the management. There are no conflicts of interest or potential conflicts of interest between the obligations of members of the Board of Directors and senior executives in respect of the Company and their private interests and/or other obligations.

Besides what is stipulated in the first and second paragraphs above, over the last five years none of the Company's members of the Board of Directors or senior executives has (i) been convicted of any matters involving fraud, (ii) being bound by a crime and/or been subject to penalties for crime by a regulatory or supervisory authority (including recognized professional associations), or (iii) been prohibited by a court to be a member of an issuer's administration, or a management or supervisory body, or to perform senior or leading functions at an issuer.

Financial information & key ratios

Historical financial information for Brighter presented in this section in respect of the 2018 and 2019 financial years, with associated auditor's reports, plus the interim report for the period January 1–September 30, 2020 with comparative figures for the corresponding period in 2019, have been incorporated in the Prospectus by reference. Incorporated documents are presented in the section entitled “Documents incorporated by reference”. The consolidated financial statements for Brighter have been prepared in accordance with Årsredovisningslagen [the Swedish Annual Accounts Act], RFR 1 Supplementary Accounting Rules for Corporate Groups, as well as the International Financial Reporting Standards (IFRS) and the interpretations of the IFRS Interpretations Committee (IFRS IC) as adopted by the EU. The above interim report has been prepared in accordance with Årsredovisningslagen [the Swedish Annual Accounts Act], RFR 1 Supplementary Accounting Rules for Corporate Groups, as well as the International Financial Reporting Standards (IFRS) and the interpretations of the IFRS Interpretations Committee (IFRS IC) as adopted by the EU, but has not been subject to review or audit by the Company's auditor. No other information in the Prospectus has been revised unless expressly stated otherwise.

The information below should be viewed together with the Company's annual reports for the 2018 and 2019 financial years, including auditor's reports, plus the Company's interim report for the period January 1–September 30, 2020 with comparative figures for the corresponding period in 2019, all of which have been incorporated in the Prospectus by reference.

The sections of the documents in which references are incorporated are:

The report for the period January 1–September 30, 2020

Consolidated income statement	Page 13
Condensed consolidated balance sheet	Page 14-15
Consolidated cash flow statement	Page 17
Notes	Page 21-26

Audited annual report for the 2019 financial year

Consolidated income statement	Page 38
Condensed consolidated balance sheet	Page 39-40
Consolidated cash flow statement	Page 41
Notes	Page 46-76
Auditor's report	Page 78-79

Audited annual report for the 2018 financial year

Consolidated income statement	Page 32
Condensed consolidated balance sheet	Page 33
Consolidated cash flow statement	Page 35
Notes	Page 40-67
Auditor's report	Page 69-71

Key ratios

Brighter uses certain financial key ratios not calculated according to IFRS. The Company feels that these key ratios provide valuable information for investors as they enable an assessment of current trends in a better way in combination with other key ratios that are calculated in accordance with IFRS. As different companies do not always calculate these key ratios in the same way, it is not certain that the information below can be compared to key ratios with the same designations as those of other companies. The Company assesses that the key ratios provide a better understanding of its financial development.

	Jan-Dec 2019	Jan-Dec 2018	Jan-Sept 2020	Jan-Sept 2019
Operating profit (KSEK)	-79,810	-48,605	-125,386	-44,781
Net financial items (KSEK)	-9,875	-4,475	-2,584	-10,377
Profit before tax (KSEK)	-89,685	-53,080	-127,970	-55,158
Balance sheet total (KSEK)	255,664	170,616	384,047	218,184
Equity ratio (%)	81%	63%	87%	94%

Definition of performance indicators

Operating profit/loss	Profit/loss before financial items	This measure is used to measure profitability of financial costs/income.
Net financial items	Financial income minus financial costs	This measure is used to show how profitable the Company's financial activities are.
Profit before tax	Profit before tax	This measure is used to show the Company's profit before tax.
Balance sheet total	Total assets on balance sheet	This measure shows the financial position of the Company in relation to the book value of the Company's assets
Equity/assets ratio %	Shareholders' equity via balance sheet total	The equity/assets ratio is relevant to investors and other interested parties who wish to assess the Company's financial stability and capacity to survive in the long-term.

Reconciliation of alternative key ratios

Equity ratio	12/31/2019	12/31/2018	9/30/2020	9/30/2019
Equity	207,775,000	106,918,000	335,894,000	205,335,000
Balance sheet total	255,664,000	170,616,000	384,047,000	218,184,000
Equity ratio	81%	63%	87%	94%

Auditor's reports

The auditor's report for financial year 2018 includes the following wording:

"Disclosure of particular importance. Without prejudice to our statements above, we wish to draw attention to the management report, which states that the Company is in need of additional capital in order to finance both the Company's long-term and short-term liquidity needs. The Company's liquidity needs depend on how successful it will be in commercializing its Actiste product in combination with whether or not funding current operational activities can be done with external funds. In order to ensure financing of the company's business, it is of the utmost importance that the financing of such takes place according to the options that the Board of Directors and management deem plausible."

Dividend policy

Any dividend will be resolved by the shareholder's meeting following a proposal by the Board of Directors. Dividend rights accrue to shareholders who are registered in the shareholder register maintained by Euroclear on the record date resolved at the shareholder's meeting. All shares in the Company are entitled to a dividend. If a shareholder cannot be contacted through Euroclear the shareholder retains claim on the Company in respect of the amount of dividend, subject to a regulated limitation period. Upon expiry of the limitation period, the full dividend amount accrues to the Company. There are no specific rules, restrictions or procedures regarding dividends payable to shareholders domiciled outside Sweden.

It is the policy of the Board of Directors to invest available funds in the business for as long as it is deemed more advantageous to shareholder value than paying a dividend. Therefore, the Board

of Directors is currently intending to allow the Company to balance any profits in order to fund growth and the running of the enterprise and consequently does not predict payment of any cash dividends over the next few years. The opportunity for Brighter to pay dividends in the future is dependent on a number of factors, such as future earnings, financial position, cash flows, the need for working capital, costs for investments and other factors.

Significant changes to the Company's financial position after September 30, 2020

On December 10, 2020 the Board of Directors, pursuant to the mandate from the annual general meeting on June 15, 2020, made a decision to implement a targeted new issue of shares amounting to approx. MSEK 33 to Unwrap Finance Nordic AB. Payment took place through offsetting of receivables of MSEK 19.8, plus MSEK 13 in cash. The subscription price was set at SEK 2.8, which was equivalent to a 10% discount compared with the volume weighted average price of the share between November 6 and December 7, 2020.

The purpose of the new issue and the reason for the deviation from shareholders' preferential rights was to reinforce the Company's financial position effectively, which the new share issue is deemed to achieve. The number of shares increased by 11,714,285, and the share capital increased by SEK 585,714.25. The total number of shares after the transaction is 229,005,540, and the share capital amounts to a total of SEK 11,450,277. The transaction is part of the financing agreement referred to by the Company earlier in its financial reporting.

Besides what is stated above, there have been no significant changes to the Company's financial position since the latest reporting period.

Legal issues, ownership and supplementary information

Shares and share capital

According to the applicable articles of association only one series of share, ordinary shares, can be issued. Each share has a quotient value of 0.05 SEK. According to the Company's Articles of Association, share capital should be at least SEK 10,000,000 and not exceed SEK 40,000,000, divided over at least 200,000,000 shares and at most 800,000,000 shares.

At the start of 2019, the Company's share capital stood at SEK 3,708,404.10 distributed over 74,168,082 shares. At the end of 2019, the Company's share capital stood at SEK 4,805,560.20 distributed over 96,111,204 shares. As of the latest balance sheet date, the Company's share capital stood at SEK 10,864,562.75 distributed over 217,290,255 shares. As of the date of approval of the Prospectus, the Company's share capital stood at SEK 11,450,277 distributed over 229,005,540 shares.

The shares in Brighter are denominated in Swedish kronor (SEK). All shares issued are fully paid and freely transferable.

Ownership and major shareholders

The Company's owners holding at least 5% of shares as at the date of approval of the Prospectus are shown below. The Company has taken no action with a view to ensuring that this control over the Company is not abused. The provisions in the Swedish Companies Act that regulate protection for minority owners do, however, provide protection from a majority owner's abuse of the Company, should it occur. As far as the Board is aware, there are no shareholder contracts or other agreements among the Company's shareholders which seek joint influence over the Company. Nor is the Company's Board of Directors aware of any agreements, or the equivalent, that can lead to a change in control of the Company.

Name	Number of shares	Percentage of votes and capital
Avanza Pension	25,030,662	11.52%
Total above	25,030,662	11.52%

Share-based incentive scheme

LTI 2020

At the annual general meeting held on June 15, 2020, a decision was made in accordance with a proposal by the Board of Directors to adopt a performance-based incentives program for employees and certain consultants at the Company or the Company's Group, LTI 2020. This program is applicable to approx. 81 Brighter employees and consultants. Following a vesting period of three years, participants will be assigned warrants in Brighter we have charge, provided that certain vesting conditions are met. For these performance share rights, as they are known, to entitle participants to allocations, participants are required to have maintained their positions at Brighter over a vesting period. For allocation to take place, performance targets based on turnover, share price and EBITDA also have to be met. The performance share rights mean that Participants in the program will be entitled to acquire one warrant in Brighter for every performance share right, with the right for its holder to acquire one share in Brighter at a price corresponding to the quotient value of the share (SEK 0.05), provided that the vesting conditions specified below are met ("**performance share right**"). The performance share rights are allocated free of charge.

LTI 2020 includes no more than the following number of Brighter employees and consultants, plus further employees or consultants to which the Board of Directors decides to offer participation in the program ("**Participants**"), which is divided into three categories as follows:

Category 1: One Participant – the Chief Executive Officer

Category 2: 20 Participants – management and key individuals

Category 3: 60 Participants – other employees

Participants in each category may be awarded no more than the following number of performance share rights, the Board of Directors dividing the Participants into each category and determining their entitlements to an allocation given the established guidelines that take into account the experience, skills and permanent salary of each Participant:

Category 1: 1,990,365 performance share rights

Category 2: No more than 220,000 performance share rights per Participant and a total of 2,985,540 performance share rights for all Participants in the category

Category 3: No more than 25,000 performance share rights per Participant and a total of 995,160 performance share rights for all Participants in the category

The maximum number of performance share rights that can be allocated according to LTI 2020 is 5,971,065, which corresponds to around 3 percent of outstanding shares and votes in Brighter. The calculation is based on 199,036,580 shares, of which 4,592,991 shares are attributable to exercised warrants that have not yet been registered with the Swedish Companies Registration Office. The total number of warrants issued in order to both facilitate delivery and guarantee costs is 7,847,173. The number of shares in Brighter will increase by 7,847,173 if the warrants are fully subscribed. These shares constitute approximately 3.94 percent of the number of shares and votes in Brighter.

The general meeting decided, in accordance with the proposal by the Board of Directors, to implement delivery and hedging measures in order to guarantee the Company's commitments as a consequence of LTI 2020.

In order to guarantee these commitments, the Company must issue 7,847,173 warrants with a right for the Company to transfer warrants to Participants in LTI 2020. The Company also has the right to transfer warrants to a third party in order to cover costs for LTI 2020, if this is necessary in order to hedge certain costs. This may, for example, be achieved by allowing the Company to enter into a swap agreement with a third party.

Board program

At the annual general meeting on June 15, 2020, a decision was made in accordance with a proposal made by shareholder Recall Capital Nordic AB to implement a performance-based incentive program for members of the Board of Directors at the Company. Unlike the situation applicable for LTI 2020, directors must earn one-third of the performance share rights for each and every one of fully completed terms of office as of the time at which the director is elected to their position after the 2020 annual general meeting. For the members of the Board of Directors to be able to exercise their performance share rights and obtain an allocation, as with LTI 2020 performance targets based on turnover, share price and EBITDA have to be reached. However, performance share rights may not be exercised until after a period of three years, even if they have been earned. Every allocated warrant gives the Participant the right to acquire one share in Brighter at a price equivalent to the quotient value of the share (SEK 0.05).

Assuming a full outcome of the performance target and the share price of no more than SEK 22.50 at the end of the vesting period, the total cost of the Board program, including social security costs calculated on the basis of 31.42 percent, is estimated to amount to no more than SEK 45,435,836.

The general meeting decided, in accordance with the proposal by shareholder Recall Capital Nordic AB, to

implement delivery and hedging measures in order to guarantee the Company's commitments as a consequence of the Board program. In order to guarantee these commitments, the Company must issue 2,023,868 warrants with a right for the Company to transfer warrants to Participants in the Board program. The Company also has the right to transfer warrants to a third party in order to cover costs for the Board program, if this is necessary in order to hedge certain costs. This may, for example, be achieved by allowing the Company to enter into a swap agreement with a third party.

If the warrants are exercised in full, the number of shares in Brighter will increase by 2,023,868, which means dilution of approximately 1.01 percent.

Significant agreements

In January 2020, Brighter acquired Nectarine Health (formally Noomi AB), Swedish innovation company that develops AI care solutions for care and nursing of the elderly. This acquisition was completed on January 31, 2020 and took place by means of an issue in kind. The transaction included all intellectual property rights, customer relations, the development organization, inventory, personnel and other assets. The purchase price amounted to approx. EUR 1.5 million and payment took place through the new issue of 2,266,682 shares in accordance with a mandate from the annual general meeting on May 9, 2019 at a price of 5.72 kronor. The share price for the issue was established by VWAP (daily volume weighted average price) based on the 10 trading days prior to entry.

Besides what is stated above, with the exception of agreements entered into within the framework of ongoing business activities, Brighter has not entered into any agreement of essential significance for a period of one year immediately before publication of the Prospectus.

Share warrants

As at the date for the Prospectus, a total of 22,090,000 warrants in Brighter have been issued, divided over three different types, each of which providing entitlement to subscription of one share. Warrants series TO5 has been issued to all shareholders in connection with the exercising of convertible facilities, and is traded on the Nasdaq First North Growth Market. Other option series (Series I, II, etc.), are part of an incentive program and have been issued to personnel, key persons and directors.

Denotation	Redemption price (SEK/share)	Exercise periods	Number outstanding
TO5	According to the terms and conditions, the recalculation can only be done after the offer. Before recalculation the strike price is SEK 6.40 per share	May 21-June 4, 2021 November 22-December 6, 2021 May 23-June 6, 2022 November 21-December 5, 2022 May 23-June 5, 2023	22,000,000
Series I 2018/2021	26.63	May 31, 2021-September 30, 2021	40,000
Series II 2018/2021	26.63	May 31, 2021-September 30, 2021	50,000

After the present rights issue, according to the terms and conditions, certain recalculations will be performed. To the extent these can be done in advance, a summary table is presented below (originally/after recalculation):

Transactions with closely related parties

2019

Affiliated party transactions in the form of payments in addition to board director fees have, in 2019, been made concerning the following board members: Jan Stålemark has drawn fees of SEK 212,550 for consulting services. Lars Flening received fees of SEK 30,000 for consulting services and Afsaneh Ghatan Bauer invoiced fees of SEK 173,530 for legal services and expenses related to trademark registration. All amounts are exclusive of VAT. All transactions were carried out on a commercial basis.

Acquisition of Camanio AB

On September 29, 2019, Brighter entered into a share purchase agreement with Camanio Care AB (publ) ("Camanio Care") regarding the acquisition of all shares in Camanio Care's subsidiary, Camanio AB.

One condition for the acquisition was that Camanio Care's business operation had been transferred to its subsidiary, Camanio AB. On the date that the share purchase agreement was entered into, Brighter owned approximately 27 per cent of the shares in Camanio Care. The transfer of Camanio Care's business operation to Camanio AB and Brighter's closing of the shares in Camanio AB took place October 14, 2019, following the approval of the sale by an extraordinary general meeting of Camanio Care. The purchase price for the acquisition of the shares in Camanio AB was SEK 17,000,000, which was paid through an issue in kind in which Brighter issued 1,597,744 shares to Camanio Care and Camanio Care transferred all of the shares in its subsidiary Camanio AB to Brighter as a consideration other than in cash. The subscription price per share in the issue in kind was SEK 10.64 kronor which corresponded to the volume weighted average price for the 20 days preceding the date of closing. The decision regarding the issue in kind to Camanio Care was adopted at the board meeting on 14 October 2019 with the mandate of the annual general meeting on 9 May 2019.

Transfer of units in Camanio Care AB (publ) to Magnanimity AB and Inti Raymi AB

On October 11, 2019 Brighter decided to transfer all of its 14,500,000 shares and 371,544 warrants in Camanio Care AB (publ) to Magnanimity AB and Inti Raymi AB.

Of these 7,250,000 shares and 185,722 warrants have been transferred to Magnanimity AB, which is a company owned and controlled by Brighter's former Chair of the Board of Directors Truls Sjöstedt. The other 7,250,000 shares and 185,722 warrants have been transferred to Inti Raymi AB, which is a company owned and controlled by Brighter's regular CEO Henrik Norström. These transfers have taken place on a commercial basis at a price of SEK 0.29 per share which corresponds to the volume weighted average price for 20 trading days prior to the transfer. In total the purchase price for the shares and warrants was SEK 4,205,000. The purchase was made in cash.

2020

Up to and including September 30, 2020, the Company has paid remuneration as follows, in addition to board fees. Jan Stålemark has received SEK 481,650 for consultancy services attributable to the implementation of OKR and SEK 600,000 by way of remuneration for his role as acting CEO of Pink Nectarine Health AB. Tove Andersson has received SEK 171,654 for consultancy services relating to blockchain.

Emanuel Lipschultz has received SEK 44,100 for consultancy services. All amounts are excluding VAT. All transactions were carried out on a commercial basis.

Proceedings by the authorities, legal proceedings and arbitration proceedings

Over the last twelve months, the Company has not been involved in any legal proceedings, arbitration proceedings or proceedings by the authorities (including proceedings that have not yet been settled or that, to the Company's knowledge, are at risk of being initiated) and that have recently had or could have significant impact on the Company's financial position or profitability.

Interests and conflicts of interest

None of the Members of the Board of Directors or members of the management has family ties to other Members of the Board of Directors or members of the management. There are no conflicts of interest or potential conflicts of interest between the obligations of members of the Board of Directors and senior executives in respect of Brighter and their private interests and/or other obligations.

Available documents

The Company's updated Articles of Association, memorandum and all documents incorporated in the Prospectus by reference in accordance with the section entitled "Documents incorporated by reference", along with the Prospectus, can be reviewed at the Company's head office at Borgarfjordsgatan 18, SE-164 40 Kista, Sweden while the Prospectus remains valid. Relevant documents are also available on the Company's website at www.brighter.se.

Please note that the information on the Company's website does not form part of the Prospectus and has not been reviewed or approved by the Swedish Financial Supervisory Authority.